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1. INTRODUCTION  
1.1 Leishmaniasis 
Leishmaniasis is a zoonotic disease caused by obligate intracellular, protozoan parasites of the 
genus Leishmania, which maintain their life cycle through transmission between sandfly and a 
mammalian host. During their life cycle, Leishmania procyclic promastigotes differentiate in 
sandflies’ gut into infective, non-dividing metacylic promastigotes. The female sandflies 
regurgitate the metacylic promastigotes together with various parasite derived 
immunomodulatroy agents and salivary components during blood feeding on mammalian 
host1. Once the metacylic promastigotes are in the mammalian host’s blood, they are taken up 
by phagocytes and transformed to the dividing intracellular form called amastigotes. The 
amastigotes then undergo multiplication within the phagocytes at the infection site until the 
host cell bursts, allowing the freed parasites to infect other phagocytic cells (Fig. 1). Since 
Leishmania parasites have several molecular patterns, which can be detected by pattern-
recognition receptors (PRRs) of the mammalian host, they should be detected during 
internalizations by macrophages. Macrophages are coated with various PRRs. The parasites 
then cause either asymptomatic or a more severe symptomatic outcome by manipulating 
macrophage’s function in multiple ways, including subverting the control of phagosome 
biogenesis and maturation1. The asymptomatic stage of the diseases pathogenesis is a very 
critical stage where it can either potentially conferring immunity to superinfection or creating 
the dangerous likelihood of reactivation, which is often associated with a more severe 
symptomatic outcome2,3. 
 Leishmaniasis has persisted for centuries as life-threatening and disfiguring parasitic 
diseases affecting about 350 million people around the world in 98 countries with an overall 
estimated prevalence of 12 million and a yearly incidence of 2 million new cases1,4,5. It is one 
of the world’s most neglected tropical diseases, affecting mainly very poor people in 
10 
 
developing countries where the patients cannot afford the costs for medication. It 
encompasses localized (skin lesions) and disseminated infection (cutaneous, mucosal, or 
visceral). Although little is known about the basic mechanisms of symptomatic divergence, 
several determinant parameters, such as host response or susceptibility, parasite genetic 
background and various environmental factors related to the vector have been commonly 
associated with the disease outcomes2,6,7. These factors significantly complicate the diagnosis, 
treatment and control of leishmaniasis. Despite its high prevalence and huge suffering it 
causes, the disease remains largely uncontrolled, with few sub-optimum treatment options, 
little clinical research interest and no effective vaccine8,9. The current treatment regimes 
against cutaneous leishmaniasis (CL) can be either topical or systemic therapy based on 
Leishmania species, geographic regions, and clinical presentations10. It has been recently 
suggested that effective intervention measurements of the disease should consider both the 
host and pathogen1. 
 
Fig. 1. Life cycles of Leishmania parasites1  
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1.1.1 Pathogen factor 
Leishmaniasis is generally caused by species of two major Leishmania subgenera, namely 
Leishmania (Leishmania) and Leishmania (Viannia). The two subgenera of Leishmania 
comprise of about 30 species, which can produce a large spectrum of clinical manifestations 
in humans. Depending on the infecting species, the parasites can induce different disease 
pathologies in a susceptible host, from asymptomatic to fatal visceral disease3. Thus, it is 
evident that each Leishmania species has its own tropism and specific clinical forms3. 
Moreover, it has been shown that virulence factors of the parasite (for example, 
lipophosphoglycan) are dependent upon leishmanial species1. For instance: While Leishmania 
donovani (L. donovani) species complex, including L. donovani, Leishmania chagasi (L. 
chagasi), and Leishmania infantum (L. infantum), almost invariably cause life-threatening 
visceral leishmaniasis (VL) that usually have no cutaneous manifestations in 
immunocompetent humans, the remaining human-infective Leishmania species usually cause 
CL, with varying degrees of severity: localized cutaneous, diffuse cutaneous, and 
disseminated or mucocutaneous leishmaniasis2,7,9. CL  is chronically disfiguring parasitic 
infections with symptoms of disease commonly caused by Leishmania tropica (L. tropica), 
Leishmania major (L. major), L. donovani, L. infantum, Leishmania aethiopica (L. 
aethiopica) and Leishmania mexicana (L. Mexicana),  whereas, the mucocutaneous 
leishmaniasis (MCL), the extension of local skin disease into the mucosal tissue, is most 
frequently caused by Leishmania braziliensis (L. braziliensis) complex, where metastasis 
occurs in 5–10% of CL patients2,9. These phylogenetic clustering supports the idea that 
symptomatic tropism is determined by species-specific parasite factors.  
Importantly, disease phenotypes of CL and VL can be replicated in mouse models. L. 
major causes progressive footpad swelling in susceptible mouse strains such as BALB/c 
following subcutaneous or intradermal injection, whereas L. donovani injection is associated 
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with high visceral organ parasite levels. Furthermore, genomic sequencing of L. infantum, L. 
major, L. braziliensis, and L. mexicana highlighted each species with specific genes that may 
be associated with difference in the disease phenotype11,12. For example, in a study comparing 
L. major and L. donovani, the ability to colonize internal organs and cause VL has been 
associated with their thermotolerance ability12. The A2 family of proteins, expressed in L. 
donovani but not in L. major that has a low thermotolerance, promote resistance to the 
warmer temperatures found in visceral organs. As a result,  the A2 gene was proposed to 
harbor a ‘visceralizing factor’, enabling parasites to withstand the heat shock of visceral 
fever13. Indeed, genetic introduction of A2 into L. major improves its ability to infect visceral 
organs while decreasing its ability to cause footpad swelling supporting the notion that 
visceral colonization is associated with heat tolerance14,15. Similarly, it has been also shown 
that interspecies differences are accounting for variability in treatment response16,17. Taken 
together, the current research data suggest that the clinical outcome of leishmaniasis follow 
the speciation of Leishmania and parasite-related factors. 
1.1.2 Host Factor 
The genetic background of the host plays another important role in resistance or susceptibility 
to infection with Leishmania parasites. It is likely to be a key parameter in the control of 
parasite burden18. Several studies genetically compared populations presenting different 
evolution patterns of leishmaniasis. Some studies identified significant associations between 
human gene polymorphisms and expression of the disease19,20. Based on the clinical 
manifestation and exposure to different Leishmania species, different patterns of 
immunological response are also observed. The phagocytes represent some of the most potent 
players in innate and adaptive immunity to infection with Leishmania, as these cells have the 
capacity to eliminate the invading pathogen due to their microbicidal effector mechanism. 
However,  once Leishmania parasite is inside the host cells, it can manipulate phagocytic cells 
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by subverting their responses to its own advantage and, thereby, successfully escape their 
microbicidal effector mechanisms21–24. The mechanisms are not fully resolved, however; it is 
believed to be multi counterbalancing mechanisms. Particularly, the cellular host immune 
system has a major role in the control of infections with Leishmania. L. major infection has 
been shown to shift a cellular immunity that is associated with cytokines such as interleukin-
(IL)-12, interferon (IFN)-γ and tumor necrosis factor (TNF)-α producing Th1 CD4+ T 
lymphocytes to humoral immunity associated with (Th2) CD4+ T lymphocytes responses that 
prevents parasite removal and facilitates its survival and multiplication in phagocytes18,25,26. 
IL-4, IL-10, and IL-13 (Th2 cell-associated cytokines) and transforming growth factor β 
(TGFβ) are capable of suppressing Th1-type responses and deactivating macrophages25,27,28. 
Moreover, modulation of leishmanicidal activity of macrophages by generation and 
suppressive effects of cytokines are well studied. The outcome of leishmanial infections is 
determined by two functionally distinct T-helper cell populations, Th1 and Th2 showing its 
dependence on the immune response of the host. While resistance to the disease is associated 
with the development of Th1 type of immune responses, susceptibility is associated with Th2. 
Indeed, this has been confirmed when pretreatment of macrophages with IFN-γ and IL-12 
induced resistance to L. major in otherwise susceptible mice, showing how potently 
immunological cross-talk is able to alter the disease pathogenesis or outcomes8.  
Leishmania infections  stimulate the innate arm of the immune system and critically 
modifies the maturation, activation and development of host phagocytes through a mechanism 
dependent on TLR29,30. It has been shown that TLR3/7/9 knock-out in genetically resistant 
mice strain become highly susceptible to L. major infection18. This study clearly showed the 
critical role of nucleic acid-sensing TLR in the Th1 and Th2 polarization that determines 
susceptibility and resistance to L. major infection. Likewise, it has been recently shown that 
the current antileishmanial drugs such as sodium antimony gluconate, amphotericin B,  
miltefosine and paromomycin have also immunomodulatory properties that can stimulate the 
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innate arm of the immune system and critically modifies the maturation, activation and 
development of host dendritic cells (DCs) through a mechanism dependent on TLR929,30.  
Moreover, it has been revealed that Leishmania spp. interfere with both the innate and 
adaptive immune systems through the exosome secretion and attenuate the phagocytic cells in 
the hosts31,32. However, our current understanding of host immune responses generated 
against Leishmania parasites is mainly based on the studies in animal models and the lack of 
large-scale or systematic human studies leaves many questions regarding the effect of host 
factors33. Therefore, translation of ideas from animal models to clinical settings is a major 
remaining challenge. However, a general consensus is that the host immune response and 
host-related factors are also critical in determining the diseases outcomes in humans. 
Altogether, the recent findings suggest the feasibility and consideration of 
immunotherapy/immunochemotherapy, aimed to modulate and activate the immune response 
in a strategy to challenge the diseases or obtain a therapeutic cure.  
1.1.3 Environmental Factors 
The clinical outcomes of leishmaniasis further vary by geographical region. Geographical 
boundaries remain the clearest demarcation among symptomatic outcomes of the disease, and 
the parasite-specific endemic regions that often corresponds with the parasite phylogeny2. For 
instance, although Leishmania is found worldwide, the majority of infections occur in the 
Paleotropics (Eurasia and Africa), whereas species of the Viannia subgenus are exclusively 
endemic in the Neotropics (the Americas), suggesting the outcomes of the disease follow 
geographical patterns2. CL is endemic in numerous regions of the subtropics and is most 
frequently caused by L. major, L. tropica, and L. aethiopica in the Paleotropics, whereas in 
the Neotropics it is caused by L. mexicana and Leishmania amazonensis (L. amazonensis), or 
L. (Viannia) braziliensis, L. (Viannia) panamensis, and L. (Viannia) guyanensis. It suggests 
that environmental factors are also playing their part in the complexity of the disease and 
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should be taken in to account in designing the control measures against leishmaniasis. 
Moreover, the data suggests that one endemic area of the disease may need different control 
measures than the others.  
1.1.4 Control and Therapy 
Two-third of all forms of leishmaniaisis prevalence is CL presentations. It is a major tropical 
infection caused by vector-borne protozoa of the Leishmania species. Its control strategies 
primarily rely on a few chemotherapeutic agents that lack appropriate efficacy, safety and 
affordability. Old world CL lesions can spontaneously heal without any need for therapeutic 
intervention in certain cases while local therapies (thermotherapy, cryotherapy, paromomycin 
ointment, local infiltration with antimonials) are WHO recommended options with less 
systemic toxicity. For complex cases, systemic treatments such as miltefosine, antimonials 
and amphotericin B formulations are recommended regimens. However, the efficiency of 
such traditional antileishmanial systemic agents is limited by toxic side effects, parenteral 
route of administration and emerging drug resistance34. The most commonly used drugs faced 
major drawbacks and the current chemotherapy tools are in a critical issue. For examples: 
Pentavalent antimonials were commonly employed as first line of treatment for many years, 
but serious side effects such as cardiotoxicity, pancreatitis, nephrotoxicity and increasing 
parasite resistance in endemic regions has limited their use33,35. Similarly, the uses of 
pentamidine, paromomycin, miltefosine, or ampohotericine B are limited by toxic side effects, 
long courses of treatment and low efficacy24,36. Furthermore, resistance to the existing drugs 
has been reported and withdrawing some drugs that are currently used in the clinic37–39. 
Although the relatively newer oral miltefosine has shown some efficacy and tolerability, the 
use of systemic pharmacotherapies against CL in general remains limited by their relative 
high cost in developing countries34.  Moreover, the intracellular locations of Leishmania add 
more challenge in impairing the accession of therapeutic drugs. As people cured 
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of Leishmania infections develop lifelong immunity, prophylactic vaccination seems to be 
feasible but an effective vaccination strategy against the diseases has not yet been successful. 
Therefore, the current control measures and therapies against leishmaniasis are inefficient and 
suboptimal, warranting a need for other alternative control measures. Discovering novel 
antileishmanial compounds as well as nanomedicine approaches with a combination therapy 
are believed to be appropriate to bridge the gaps.  
1.2  Nanomedicine  
Nanomedicine is an emerging interdisciplinary field involving application of nanotechnology 
for the prevention, diagnosis and treatment of disease at the molecular level. Recent rapid 
advancement in innovation and discovery in sciences including fields of materials and life 
sciences are leading to exciting progress in the development of nanomedicines40. Many 
diseases originate from changes in biological processes that result from mutated genes, 
misfolded proteins, and infections caused by microbes at the molecular or nanoscale level41,42. 
Moreover, many biological molecules including oligonucleotides, polysaccharides, and 
proteins that function as antigens, allergens or pathogen-associated molecular patterns have 
nanoscale sizes42. The size, charge, shape and chemical properties of these nanoscale size 
molecules/pathogens appear to dictate their transport to distinct cellular compartments, 
interactions, immune response and their biomedical applications41,42. For example, regardless 
of their great promise for a significant improvement of treatment against many diseases, 
nucleic acids therapies are severely hindered by their large size, instability in biological fluids 
and negative charge that will result in poor cellular uptake and inefficient biomedical 
applications43. Thus, many synthetic and natural cationic polymers are commonly used as 
nucleic acids carriers by forming polyplex (any complex of a polymer and DNA) 
nanostructures due to their ability to condense nucleic acids into smaller particles, while 
allowing it to dissociate once inside the cell44,45. Loading or enclosing the nucleic acids within 
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a polymer or nanoparticles (NPs) could overcome the challenges in their applications by 
crossing the physiological or cell barriers and achieve delivery to the target cells. NPs are 
nanoscale in size and can be engineered due to their unique physical and chemical properties 
to improve the distribution and performance of the target molecules. The development of 
novel NPs has received much attention in recent years. It is expected that physicochemical 
properties such as size, shape, and surface chemistry of the NPs will dictate their carrier 
behavior within the body or cellular interactions and responses. This NPs’ behavior 
consequently affects the functions of the target molecules. NPs can be prepared from a variety 
of materials such as proteins, polysaccharides, metals, organic compounds, nucleic acids, 
synthetic polymers or hybrid systems (Fig. 2). Among the various nanomedicine approaches, 
the development of medicines containing NPs suspension has enabled to increase the 
therapeutic index of many drugs46,47. Due to their smaller size (one million times smaller in 
size than a millimeter), NPs can effectively transport molecules/drugs to the target site by 
overcoming the physiological or cellular barriers. Consequently, once they are loaded with the 
functional molecules/drugs, NPs can effectively transport them to the target site. The loading 
is incorporation of functional molecules into the systems without any chemical reaction; this 
is an important factor for preserving the drug/molecule activity. Moreover, NPs can be used in 
vivo to protect the target molecules entity in the systemic circulation, restrict access to the 
chosen sites and to deliver them at a controlled and sustained rate to the site of action. 
Furthermore, production of highly potent drugs or imaging agents often possess 
physicochemical and/or biological characteristics that make their use suboptimal in humans48. 
NP-based delivery platforms have many applications in biomedical sciences such as imaging, 
clinical diagnostics and therapeutics by virtue of NPs’ large surface area to volume ratio. 
Therefore, nanomedicine approaches may overcome pitfalls in sensitivity of diagnostic tools, 
therapeutic effectiveness, toxicity of drugs, or immunogenicity of vaccines46,49,50. 
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Fig. 2. Schematic illustration of various types of nanotherapeutic platforms that are being 
used in clinics51. 
1.2.1.  Nanomedicine applications in drug delivery systems  
The applications of nanomedicine in drug delivery systems have become a key tool to 
overcome the main drawbacks of chemotherapeutics and to enable their selective targeting to 
specific diseased cells and tissues. Many promising drugs or drug candidates have the 
problem of reaching their target site and the concept of NP-based drug delivery systems can 
play a significant complementary role in shaping these modern medicines. For drug delivery 
applications, selection of appropriate NPs and drugs are very crucial. Major factors such as 
inherent properties of the target drug, e.g., aqueous solubility and stability, biocompatibility 
and toxicity, surface characteristics such as charge and permeability, degree of 
biodegradability of the NPs or nature of drug release profile desired should be considered 
during the initial design for nanomedicine applications. The major goals in designing NPs for 
drug delivery systems are to control particle physicochemical properties and release of the 
drug to achieve the site-specific action at the therapeutically optimal rate and dose regimen. 
Excluding many more drugs that are being studied in clinical trials, NP-based 
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chemotherapeutics for six cancer and more than 11 other diseases have been so far approved 
for clinical use52. Among which, liposomal drugs and polymer drug conjugates are two 
dominant classes of formulations.  
The delivery of therapeutics with intracellular sites of action for which cellular uptake is 
inefficient may be best achieved with targeted delivery vehicles53. Targeted drug delivery is a 
method of transporting drugs to a patient in a manner that increases the concentration in some 
parts the body organ or cells relative to others.  Moreover, multidrug resistance (MDR) is the 
common treatment challenges in many human diseases including leishmaniasis. Some of the 
mechanism of MDR includes a decreased influx of drug, increased efflux of drugs and altered 
drug targets. In the case of leishmaniasis, for instance, drug resistance against miltefosine has 
been reported in the last few decades and the resistance mechanisms are exclusively 
associated with dysfunction  in miltefosine uptake system or poor access to intracellular 
targets54. Thus,  intracellular delivery approaches and/or modulating macrophage uptake have 
been suggested to overcome the drug resistance problem  against miltefosine54–56. Currently, 
NP-based drug delivery systems provide alternative strategies to circumvent MDR in several 
diseases57,58. Moreover, nucleic acid-based therapeutic molecules are a new approach for 
targeting of specific, prominent and essential genes responsible for causing diseases. Thus, 
they have specific anti-sense and anti-gene inhibition effect on target molecules due to 
sequence selectivity toward DNA and RNA for silencing. Such therapeutics are currently 
representing a growing number of applications in drug development pipelines59. However, the 
major limits in the use of nucleic acids therapeutics are their poor ability to penetrate across 
the cell membrane into the cytoplasm and insufficient capability to reach intracellular targets. 
Therefore, effective drug delivery systems could able to convert these poorly soluble, poorly 
absorbed and labile substances into promising deliverable drugs for efficient uptake and better 
results. In general, advanced NP-based drug delivery system is superior to existing therapeutic 
strategies and a more effective method to induce enhanced cellular uptake, maintain sustained 
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drug release, and improve bioavailability60. It is also possible to deliver large macromolecule 
drugs to intracellular sites of action or co-delivery of two or more drugs or therapeutic 
modality for combination therapy through nanomedicine approach53.  
Efficient drug loading and controlled release mechanism are other important determinants 
to establish effective drug delivery platforms. Efficient drug loading may be achieved through 
encapsulation, covalent linking and non-covalent or self-assembly methods.  Internal stimuli-
responsive NP formulations by keeping a check/control over certain specific parameters like 
pH, hydrolytic, enzymatic degradation, ionic strength, temperature, as well as externally 
applied stimuli such as magnetic field, ultrasound or light have been developed to trigger site-
specific drug release61,62. Intracellular delivery, with efficient intracellular release, have 
become important design considerations in NP formulations63. In cancer, the tumor 
microenvironment like low pH, elevated redox potential, over-expressed enzymes and 
hyperthermia has helped to design NP which can respond to such variety of intrinsic 
circumstances. Therefore, nanomedicine approaches is a promising strategy to overcome the 
current challenge of traditional chemotherapy and effectively target human diseases including 
CL.  
1.2.2. Nanomedicine applications in vaccine  
The technology of vaccine development has been radically changing and there are currently 
several successful vaccines available. Despite the huge success, there are still a large number 
of diseases including leishmanisis against which there is still no effective vaccine currently 
available. This is because the pathogens causing such diseases are mastering either immune 
escape or immune evasion64. To address such challenges, increasing both the basic 
immunological knowledge and also the development of advanced materials and techniques in 
the field of vaccinology (nanovaccine) are needed65. Three critical elements are essential in 
the composition of an effective vaccine; an antigen which induces an adaptive immune 
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response, an adjuvant which stimulates the innate immune system and influence the profile of 
the elicited immune response, and a delivery system which insures optimal delivery of antigen 
and/or adjuvant for effective activation of the immune system. Once a useful set of antigens 
and adjuvants are selected, they should be formulated in such a way that a robust immune 
response is induced. Although the subunit vaccines have an excellent safety over other 
traditional vaccine formulations such as live-attenuated or inactivated/killed pathogens, they 
have inherently weak immunogenicity and short-term immune responses that necessitate for 
novel formulation with immunopotentiating adjuvants.  
The evolving use of nanomedicine in vaccination has resulted in several promising 
formulations that increases effectiveness by inducing a more efficient immune response42,66. 
NP mimic invading pathogens and provide adjuvant activity by either enhancing the delivery 
of antigens to the immune system or by potentiating innate immune responses via their 
intrinsic immunostimulatory properties42,67. They activate antigen-presenting cells (APC) via 
TLR signaling and/or autophagy induction pathways with increasing corresponding cytokines 
and subsequent induction of innate immunity68–71. By such approaches,  particularly nucleic 
acid-based adjuvants with intracellular targets like unmethylated cytosine-phosphate-guanine 
oligodeoxynucleotides (CpG ODN) have been shown to  enhance vaccine efficacy at a low 
adjuvant dose for inducing potent and long-lived cellular immunity50,72. Several groups have 
shown that NP-based co-delivery systems also reduce the amount of antigen and adjuvant 
required to activate T cells as compared to concomitant administration of equal amount of 
respective antigen and adjuvant in vitro and in vivo68,69,73. Several molecules can also be 
combined for optimum efficacy of a nanovaccine. Thus, in order to ensure the optimum 
presentation to both innate and adaptive type of immune system, use of nanovaccine such as 
vaccine formulations containing liposomes, polymers or NPs are of great importance. 
Nanovaccines have multi-fold advantages over traditional vaccines; 1) they can serve as a 
point source for antigen retention and release in a sustained manner so that not only the 
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quantity, but also the quality of immune responses is enhanced; 2) they have the capacity to 
induce presentation of antigens through both MHC class I and MHC class II complexes; 3) 
they protect the immunogens from rapid degradation and clearance while increasing their 
stability; 4) they are readily taken up and processed by APC; 5) they mimic the natural 
process of infection and give a possibility of codelivery of several immunogens, being either 
several antigens or antigens and adjuvant molecules and 6) they permit organ- and cell-
specific targeting via surface modifications of particles with functional moieties and targeting 
ligands67,74,75. Moreover, side effects might be decreased upon encapsulation of the adjuvant 
or the concomitant delivery of antigen and adjuvant64.  
1.2.3. Nanomedicine applications in diagnosis 
Application of nanomedicine in diagnosis includes engineering NPs in order to achieve 
enhanced or novel magnetic, optical, and electronic properties that can operate at the 
biomolecular level76. Incorporating NPs into the existing clinical diagnostic and detection 
systems have demonstrated improved sensitivity and specificity of diagnosis compared to 
traditional approaches77. It greatly enhances early and accurate diagnosis. Moreover, it has 
been recently shown that NP-based diagnosis is rapid and offers clinicians the opportunity to 
diagnose multiple human pathogens within hours of sample collection78.   NPs usually have 
rich surface chemistry that allows a variety of other molecules to be loaded or attached for the 
introduction of specific functionalities. Functionalizing the NPs in combination with targeting 
agents (antibodies and their fragments, nucleic acids, or other receptor ligands like peptides, 
vitamins, and carbohydrates), and probes for fluorescent and/or magnetic resonance imaging 
can be used to develop novel sensing and diagnostic techniques. However, there are 
limitations in the density and selectivity of these targeting molecules on target cells relative to 
normal cells so as to deliver enough concentration of molecules needed for efficient 
diagnosis. Moreover, the blockage of NPs tumor targeting ligands by a serum proteins or 
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protein corona from binding to tumor cell receptors in the blood. As a result, less than 10% of 
all systemically administered NPs formulations accumulates in tumor79. In contrast, serum 
proteins adsorb onto NPs encourages uptake by macrophages, which makes easier to target 
pathogens residing inside macrophages. Recently, theranostics, a combination of diagnostic 
and therapy by incorporating drugs to the integral components needed for diagnosis is 
becoming of great interest in order to simultaneously perform the disease identification and 
therapy.  
1.2.4. Interactions of NPs with biological systems 
Consensus has been reached by now that NPs are not only carriers for biomedical 
applications, but can also play an inherent active role in mediating biological effects80. For 
instance, some NPs can inherently induce immunological responses while others have 
antimicrobial effect in addition to their carrier activity44,45. NPs have two interdependent 
identities for such effects: the synthetic identity which is comprised of its intentionally 
designed physicochemical properties such as its size, shape, surface chemistry, and surface 
functionalization, and the biological identity which is produced after adsorption of blood 
proteins onto the NPs surface (protein corona) after introduction into the biological systems. 
The synthetic identity is used to design a desirable biological identity. However, the 
biological identity is determinants of its behavior and function within the body by causing 
unexpected changes in cellular interactions, cellular uptake, biodistribution, and 
immunogenicity79. The knowledge of how NPs properties change within a biological 
environment can lead to the rapid development of key applications, including improved 
delivery system, and resolution of their potential threat to organisms and the environment. It 
can also determine the performance of NPs by impacting on its transport and drug release.  
In biological fluids, proteins bind to the surface of NP to form a coating known as the 
protein corona, which can critically affect the interaction of NPs with living systems, and, 
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therefore, further cellular/tissue responses depend on the composition of corona81,82. The 
structure and composition of the protein corona depends on the physicochemical properties of 
NPs, the nature of the physiological environment (blood, interstitial fluid, cell cytoplasm, 
etc.), and the duration of exposure83. For example: NPs surface charge is an important factor 
in protein interaction and it has been reported that increasing the surface charge of NPs 
increases the protein adsorption84. As a result, the protein corona alters the size and surface 
properties of the particle, giving it a new biological identity and, consequently, increases the 
NPs size by 3–35 nm, and changes the surface charge to −10 to −20 mV84–86. This biological 
identity determines the physiological response including agglomeration, cellular uptake, 
circulation lifetime, signaling, kinetics, transport, accumulation, and toxicity. Moreover, 
targeted therapy is a central concept in nanomedicine research. It exploits the 
(over)expression of surface receptors in target cells by ligand incorporation. However, the 
main challenge is after introduction in the bloodstream, the NPs surface is immediately 
modified by protein corona and it would be difficult to preserve the surface functionality87. 
Thus, parameters including evasion of the immune system, stability in physiological media, 
control over the interaction of NPs with biological entities such as proteins and cell 
membranes, low toxicity, and optimal bioperformance are critical factors for efficient design 
and applications of NPs in nanomedicine76.  
Over the past years, considerable numbers of studies have been conducted to 
understand the route through which NPs are taken up by different cells. The results indicate 
that NPs entry predominantly takes place through endocytosis mechanisms operating in 
mammalian cells88,89. These distinct endocytotic pathways have been characterized on the 
basis of their differences in ultrastructure, pharmacology, cargo (membrane protein, or 
receptor plus ligand) and coat protein composition90–92. The ultrastructural morphology of 
nascent endocytic intermediates at the plasma membrane provides a crucial parameter for 
classifying endocytic pathways90. Typically, endocytosis occurs by multiple mechanisms that 
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fall into two broad categories: 'Phagocytosis' or cell eating by which cells internalize large 
solid particles, and 'pinocytosis' or cell drinking, where cells take up both fluid and solutes 
from their environment. Phagocytosis is an endocytic process exhibited by several types of 
cells, including epithelial cells, fibroblasts and immune cells. Its unique characteristics 
includes a larger size of the endocytosed vesicles (>250 nm) known as phagosomes.  
Phagocytosis can be induced either through receptor-ligand interactions or through receptor-
soluble factors interactions that recognize the foreign agent and facilitate opsonization40. 
Pinocytosis can be further sub-classified and at least four basic mechanisms can be 
distinguished: macropinocytosis, clathrin-mediated endocytosis, caveolae-mediated 
endocytosis, and clathrin- and caveolae-independent pathway93,94. Macropinocytosis is an 
actin-driven endocytic process by which many types of cell internalize considerable volumes 
of extracellular fluid through large vesicles (diameter of 0.5–10 μm) known as 
macropinosomes95. It is plasma membrane protrusions or ruffles that collapse onto and fuse 
with the plasma membrane by trying to generate large endocytic vesicles (unlike 
phagocytosis, these protrusions do not 'zipper up' along the NPs). Clathrin-dependent 
endocytosis is the most studied process for trafficking of materials into eukaryotic cells which 
vesicle formation starts with membrane invaginations forming a more or less homogenous, 
symmetric polygonal lattice. Caveolin-dependent endocytosis are a smooth flask-shaped 
invaginations (60–80 nm) of plasma membrane that are abundant in several types of cells, 
such as fibroblasts, smooth muscle cells, adipocytes, and endothelial cells, and are absent in 
neurons and leukocytes40. Clathrin- and caveolin-independent pathways are several entry 
pathways characterized by polymorphous or tubulovesicular membrane invaginations. Unlike 
Clathrin- and caveolin, it does not require the presence of coat proteins for vesicle formation 
and internalization; however, the actin and actin-associated proteins are important players for 
vesicle formation. The identification of several uptake routes and pathways complicates the 
study of the cellular uptake of NP. Furthermore, these uptake mechanisms have been shown 
26 
 
to be highly influenced by the physicochemical properties of NPs including size, surface 
functionalization, geometry and other factors like concentration, time or cell types96–99 making 
the comparison of different findings even more difficult.  
In multicellular organisms, the distinct endocytic pathways are highly regulated to 
control all aspects of intercellular communications including hormone-mediated signal 
transduction, immune surveillance, antigen presentation, and cellular and organismal 
homeostasis93,100. As a result, one of the goals of designing NP-based delivery systems is to 
be able to correlate uptake routes with the physicochemical properties of the engineered NPs 
in order to guide the entry into the cell and, consequently, control the cellular responses40.  
For example, it has been shown that  the cellular uptake rate is higher in cationic (e.g. with 
COOH surface charge) as compared to in the neutral (plain) or anionic (e.g. with NH2 surface 
charge) NP in different cell types, concluding  that the particle size and surface charge are 
critical factors in influencing cellular uptake83,101,102. Ligand-targeted NPs for receptor-
mediated cellular internalization are also a good strategy for modulating the cellular uptake 
and have been the main impetus behind the progress of nanomedicines towards the clinic. 
Moreover, Karlson et al. described that bone marrow-derived dendritic cells use caveolin-
dependent pathways to take up 40-50 nm polystyrene NPs70. Thus, unlike most other NPs, 
they do not induce extracellular signal-regulated kinases that mediate inflammatory pathways 
during their applications in vaccines. Moreover, since the targets of many therapeutic agents 
are localized in subcellular compartments, modulation of NP-cell interactions is needed for 
their precise delivery to subcellular compartments40. Thus, understanding the interactions of 
NP with biological systems at the cellular and subcellular level is a prerequisite for their 
efficient and safe application in biomedical sciences. It aids in the design of NPs for effective 
biomedical applications by controlling their physicochemical properties, composition, and 
formulation process82.  
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2. RATIONALE AND OBJECTIVES OF THE STUDY 
The control of leishmaniasis mainly depends on a few chemotherapeutics that lack safety, 
efficacy and affordability. Unfortunately, vaccination against leishmaniasis has not been yet 
successful either. There is no optimum treatment option against leishmaniasis. Particularly, 
the treatment of CL is very challenging as its treatment needs both reducing the size of the 
ulcers on exposed parts of the body for healing with minimal scarring as well as eradicating 
the intracellular parasite causing the lesions. Hence, wound healing processes are important 
determinants of CL treatment103. Currently, parenteral administration of antimonials, 
pentamidine, amphotericin B or oral miltefosine is the standard systemic treatments measures 
against CL. However, due to their severe unwanted side effects that often lead to unfavorable 
risk-benefit ratios,  a topical or local treatment has been recently recommended as first line 
treatment approach for CL patients5,10,104,105. Paromomycin ointment and local infiltration 
with antimonials are good alternatives for local treatment against CL; however, they have not 
yet provided a strong consistent result. Although such local treatment usually allows higher 
drug concentration at the site of infection, reduced systemic toxicity, faster time to healing 
and reduced cost, the treatment of CL remains sub-optimal. Overall, there is a lack of 
evidence for potential benefit of the current CL treatments. WHO recommended a simple 
wound management as a first line treatment approach for non-complicated CL cases. 
Moreover, after decades of research, there is still no new commercial drug for use in the near 
future against CL. The ongoing research on CL treatment is also one of the areas of neglected 
tropical diseases research. Furthermore, there is no assurance that the development of new 
drugs can catch up to the pathogens’ fast and frequent development of resistance in a timely 
manner. In addition, leishmaniasis mainly affects the poorest regions of the world where the 
patients cannot afford the costs for medication, a fact that severely discourages the 
pharmaceutical industry to invest in this field. Hence, there is an urgent need for discovery of 
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novel antileishmanial compounds and/or alternative treatment approaches against CL. 
However, due to the high costs associated with drug identification and development, 
discovery of novel drugs against CL may not be attractive.  
Topical or local treatment has been recommended by WHO as a first line treatment 
approach for CL patients5. However, the efficacy of the drugs are generally hindered by  the 
intrinsic antileishmanial activity of the drugs and the amount of drug available in the dermis, 
suggesting a need for improved drug absorption and retention strategies106,107. Importantly, it 
has been shown that liposomes loaded with drugs enhanced in vitro drug permeation across 
stripped skin and improved the in vivo antileishmanial activity in experimentally infected 
mice35,56,108. Insights into the most promising delivery strategies to improve treatment of CL 
could enhance skin delivery and efficacy of conventional antileishmanial drugs35. Moreover, 
the challenge of the current conventional leishmaniasis treatment is partially because of the 
failure of drugs to penetrate macrophages where the parasite hides24,49. Since macrophages are 
prominent sites for microbial infections such as L. major, particle formulations that are easily 
taken up by macrophages would be highly advantageous for macrophage-targeting drug 
delivery. The particle formulations can be efficiently taken up by macrophages and 
consequently, increases intracellular drug concentration for an efficient pharmacological 
effect against intracellular L. major. Thus, an effective therapy could be achieved through 
delivering antileishmanial drugs to the site of infection and releasing the drug in a controlled 
manner. However, in the past 35 years of research in the field of drug delivery, AmBisome 
(Amphotericin B liposome for injection, Astellas Pharma US, Inc.) is the only drug delivery 
system currently used against leishmaniasis109,110. Though AmBisome is decreasing its uptake 
by kidney cells and thereby reducing its nephron toxicity, it is relatively less active and more 
expensive than free amphotericin B and also associated with central nervous system 
toxicity111,112. As a result, practically there is no optimal drug delivery system that may 
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enhance the antileishmanial activity of drugs through crossing the physiological or cell 
barriers while reducing or avoiding their host toxicity.  
The emerging nanomedicine approaches, particularly advanced drug delivery systems, 
have currently been found to increase the antimicrobial efficacy in many cases. However, 
their successful applications require a thorough understanding of NPs’ physical and chemical 
properties and how they interact with host cell. This is because in order to transport 
pharmaceutically active compounds in the body, NPs should interact with all sort of 
biological systems that determine their safety and applications to achieve a desired therapeutic 
effect. It has been suggested that alterations in the physicochemical properties of NPs can 
regulate uptake mechanisms and the intracellular fate of NPs94,97,99. A great deal of scientific 
efforts have focused on understanding and controlling the NPs internalization pathways to 
facilitate the development of NPs that can perform precise intracellular targeting with 
enhanced therapeutic outcomes40. Regardless of the efforts, a complete understanding of how 
cells interact with nanostructures of well-defined sizes, at the molecular level, remains poorly 
understood and  there is little consensus in the literatures regarding this issue. It has been 
suggested that the accurate knowledge of NP uptake mechanisms and NP-cell interactions are 
an important criterium to progress in the field of nanomedicine88,89,94.  
On the other hand, recent data suggested that immunotherapeutic approaches are 
promising methods for effective treatment of leishmaniasis10,106. Leishmania parasites resides 
in phagocytic cells that include neutrophils, macrophages and dendritic cells; therefore, an 
immunomodulatory compound could be potentially leishmanicidal by virtue of its potential to 
activate phagocytic cells113. A curative response against leishmaniasis depends on the 
classical activation of phagocytes and the IL-12-dependent onset of an adaptive type 1 
response characterized by the production of IFN-γ6,26. It has been shown that CpG ODN alone 
or in combination with other antileishmanial drugs show a promising efficacy against L. 
major114. This can be further verified by the fact that many antileishmanial compounds 
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including current conventional drugs have either immunomodulatory activity, or rely on the 
host immune system for their effect113. Thus, besides discovering new compounds and 
establishing advanced drug delivery systems against leishmanaisis, a combination therapy that 
employs both host- and pathogen-directed treatment may represent feasible alternatives. This 
may include a combination therapy that comprising chemotherapy and biological therapeutics 
that act through manipulating the host immune system (immunotherapy). Although 
considerable success has been attained using combination therapies, none has yet achieved 
commercial status. Well-designed mechanism-based combinations therapies (drugs acting 
through different mechanisms) that target the host and the parasite may improve treatment by 
reducing the length of treatment, relapse, and risk of toxicity and increases the therapeutic 
index. As a result, combination therapy that is targeted to simultaneously kill the parasites and 
manipulate the host immune system in favor of cellular parasite removal (killing) is of 
particular interest. 
Developing an effective topical treatment for CL using antileishmanial drugs still 
remains a great challenge35. Regardless of the advances in basic scientific research, there has 
been little progress in new drug development, and the overall outcomes of current treatments 
for CL are far from ideal therapy. Effective and safe therapies that are readily accessible to 
third-world countries are urgently needed. It requires effective killing of intracellular 
amastigotes and enhancing lesion or wound closure caused by CL. In these contexts, 
polyhexamethylene biguanide (PHMB; CAS# 27083-27-8; alternative chemical names: 
polyhexanide, polyamino propylbiguanide, Mw = 2780 g/mol)
115  is an “old” antimicrobial 
polymer and wound antisepsis that is widely used in clinics, homes and industry was 
investigated for CL treatment. It is a very cheap synthetic polymer that is recommended as a 
treatment choice for locally infected and critically colonized wounds with no evidence for the 
development of resistance against several bacteria in many parts of the world including 
Europe and the US for over 50 years116. It is also widely used as preservative, contact-lens 
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multipurpose solutions and general care purposes, with excellent tolerance and a low-risk 
profile lacking any systemic toxicity117–119. Furthermore, PHMB is being frequently used in 
clinical treatment of Acanthamoeba keratitis patients120,121. However, there is no information 
about the use of PHMB as treatment for trypanosomatid protozoan diseases in general and 
Leishmania infection in particular, and there have been no attempts to evaluate PHMB as 
treatment for CL. Given its cheap cost and excellent toxicity profile, PHMB may be a 
promising candidate for effective treatment of CL.   
Taken together, exploring potential strategies to identify novel, effective and 
affordable chemotherapeutic agents in parallel to exploring alternative treatment approaches 
to improve the existing drugs against leishmaniasis are urgently needed. It has been suggested 
that current nanomedicine approaches are believed to be an appropriate alternative to address 
the treatment challenges against CL35. In light of the time required to bring a new drug to 
market and the cost involved, a combined therapy with alternative advanced drug delivery 
systems seems to be feasible options for effective treatment of leishmaniasis. This strategy 
includes designing novel NP carrier and loading it with the components of combination 
therapies for safe and effective treatment. It would then lead to reductions in the duration of 
conventional treatment, better patient compliance, and the prevention of antileishmanial drug 
resistance or toxicity. Therefore, the general objectives of my PhD research project were 
aiming at identifying novel antileishmanial agents and using a nanomedicine approach to 
address the current treatment challenges of CL. The specific objectives of the study were to: 
• Discover novel and affordable topical antileishmanial compound for the treatments of 
CL patients, 
• Systematically understand how NP interacts with mammalian cells for safe and 
effective usage in nanomedicine,   
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• Establish a mechanism based host- and pathogen-directed combination therapy with 
innovative NP-based drug delivery systems against CL. 
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3. MATERIALS AND METHODS  
3.1 Nanoparticles and drugs 
Two different types of polymer NPs were used in this study. Primarily, fluorescent 
polystyrene latex beads of different sizes (0.02 μm, 0.1 μm, 0.2 μm, 0.5 μm, 1 μm and 2 μm) 
were purchased from Life Technologies (F-8888, Darmstadt, Germany) at 2% solids and used 
without any further modification. They were used as a model to analyze the uptake and 
endocytosis pathways, which play a key role in the clearance of drugs. The NPs were 
sonicated (Bandelin Sonorex Super RK 106, Berlin, Germany) for 10 min immediately prior 
to every experiment.  Secondly, PHMB was kindly provided by Dr. Liam Good, University of 
London, and Tecrea Ltd, London UK, at stock concentrations of 1 mg/ml and 200 mg/ml.  
Standard antileishmanial drugs including amphotericin B (A2942), pentamidine 
isothionate (P0547) and paromomycin sulfate (P9297) were purchased from Sigma-Aldrich 
(Deisenhofen, Germany) and were used as positive controls. Similarly, miltefosine (1- 
hexadecylphosphorylcholine) from Cayman Chemical Company, Ann Arbor, MI, USA was 
used as standard antileishmanial positive control compound. FM4-64FX dye (F34653) which 
is a fixable analog of FM 4-64, Hoechst 33342 (H3570) and LysoSensor Blue DND-167 (L-
7533) were similarly purchased from Life Technologies and used according to the supplier’s 
instructions. AlamarBlue cell viability assay reagent was purchased from Trinova Biochem 
GmbH (Giessen, Germany) and was used according to the manufacturer's instructions. To 
investigate the cellular uptake mechanisms of polymer NP based on specific pharmacological 
inhibitors, chlorpromazine hydrochloride (C8138), cytochalasin D (C8273), ikarugamycin 
(SML0188), wortmannin (W1628), and dynasore (D7693) were purchased from Sigma-
Aldrich (Deisenhofen, Germany). Oligodeoxynucleotides containing unmethylated cytosine-
phosphate-guanine (CpG ODN 1668, Mw = 6058 g/mol) and rhodamine red-labeled CpG 
ODN (CpG-R, Mw = 6891 g/mol) lyophilisates with the same sequence 
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TCCATGACGTTCCTGATGCT were purchased from Eurofins MWG Operon (Ebersberg, 
Germany) and were diluted in  distilled water and used at various concentration.  
3.2 Cell culture  
Primary bone marrow-derived macrophages (BMDM) were generated from bone marrow of 
BALB/c mice (Charles River Breeding Laboratories, Sulzfeld, Germany) as previously 
described122. The particular mouse was sacrificed by cervical dislocation in laboratory animal 
facility at Institute for Molecular Biology (IMIB), University of Würzburg and taken to 
laboratory. After disinfecting all external surfaces with 70% ethanol, tibia and femur were 
surgically removed by using pre-heat sterilized scissors and forceps without damaging the 
epiphysis. After brief disinfection in 75% ethanol, the bones were placed into a 50 ml 
polypropylene tube containing phosphate-buffered saline (PBS). The bone marrows were then 
opened by cutting both tips of the bones with a sharp sterile scissor in conditioned Dulbecco's 
Modified Eagle Medium (DMEM). The conditioned  medium contains supplementary nutrients 
or compounds such as 10% heat-inactivated fetal calf serum (FCS), 5% horse serum (heat-
inactivated), 50 μM β-mercaptoethanol, 10 mM HEPES buffer, 4 mM L-glutamine, 1% non-
essential amino acids and 15% L929 macrophage-colony stimulating factor (M-CSF) that was 
generated from L929 fibroblasts as indicated below. The bone marrows were flushed with the 
conditioned medium in a 1 ml syringe (with 26G needle) by inserting the needle into the tip of 
the bones. The stem cells were then collected in 50 ml polypropylene tube and washed at 300 × 
g (10 min, 4°C) and counted by using a Neubauer chamber (0.1 mm depth) after 1:10 dilution 
in trypan blue solution. After the stem cells numbers were adjusted to 1.2 × 105 cells per ml by 
the same conditioned medium, 10 ml of cell suspension was added to culture dishes (20  100 
mm suspension plates; Sarstedt, Nümbrecht, Germany) and incubated at 37°C and 5% CO2 for 
6 days.  The primary BMDM were harvested by using cell scraper and maintained in complete 
Roswell Park Memorial Institute (RPMI) medium containing 10% FCS (heat-inactivated), 2 
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mM L-glutamine, 10 mM HEPES buffer, 0.05 mM β-mercaptoethanol solution, gentamicin (50 
µg/ml) and penicillin G (100 u/ml). The percentage of BMDM was confirmed by flow 
cytometry after staining with F4/80 macrophage marker and more than 85% cut off value were 
considered acceptable as compared to the isotype control. At this point, BMDM are ready for 
biological experiments.   
M-CSF supernatant was generated from L929 fibroblasts (Leibniz DSMZ, German 
Collection of Microorganisms and Cell Cultures, DSMZ-No ACC-2, Braunschweig, 
Germany) in special medium containing 500 ml 1×DMEM (Gibco 21969),  0.25 µM 2-
mercaptoethanol (Sigma Aldrich M-7154), 1% non-essential amino acids (Gibco 11140),  5% 
heat-inactivated FCS, 1% penicillin/streptomycin solution (Gibco 15140), 4 mM L-glutamine 
(Biochrom AG K0282) and 10 mM HEPES buffer. The subculture tube containing L929 cells 
were taken from the stock in liquid nitrogen tank. The tube was put in pre-warmed water bath 
to thaw subculture cells until only a bit of frozen cells left at the bottom of the tube. 700-800 
µl of pre-warmed medium was added to the cells, resuspended and transferred into 15 ml 
polypropylene tube containing 10 ml of the pre-warmed medium. The bottom of the tube 
containing cells was washed once more with 200-300 µl of medium and added to the rest of 
the cells. The cells were then briefly centrifuged at 68 × g, 4°C for 10 min to wash out the 
DMSO. The supernatant was discarded and the pellet was resuspended with 30 ml medium. 
The cells were then transferred to culture flasks and cultivated at 37°C, 5% CO2 for two to 
three days (1st passage). When the L929 cells were about 70-80% confluent, the passages 
were continued for second and third times. On the fourth passage, the cells were harvested by 
gently scraping, centrifuged at 300 × g, 4°C for 10 min and counted in trypan blue. The cell 
numbers were adjusted to1 × 105 cells/ml. 30 ml of the cell suspensions were added to flasks 
and further incubated for about 10 days to get enough M-CSF productions. Finally, the M-
CSF supernatant were transferred into 50 ml tubes, centrifuged at 300 × g, 4°C for 10 min, 
filtered and stored at -20 °C in a desired aliquot until used. 
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 For 293T kidney epithelial cell lines (DSMZ-No ACC-635, Braunschweig, Germany) 
and L929 fibroblasts (Leibniz DSMZ, German Collection of Microorganisms and Cell Cultures, 
DSMZ-No ACC-2, Braunschweig, Germany) were cultivated and maintained in high glucose 
(4.5 g/l) DMEM without L-glutamine and phenol red but containing 10% fetal calf serum (heat-
inactivated), 200 mM L-glutamine and sodium pyruvate for at least two consecutive passages 
before use. The epithelial cells were trypsinized to obtain single cell suspensions, diluted 1:10 
in trypan blue and counted in the same Neubauer chamber. The numbers of cells in all the three 
cell types were adjusted to 2 × 105 cells per ml for all cell types and respective experiments.  
3.3 Flow cytometry 
Cells were grown as described in cell culture and were harvested, treated with different 
concentrations of fluorescent NPs (Polystyrene and PHMB), CpG-R, PHMB/CpG-R 
polyplexes and PHMB-FITC/CpG polyplexes for different time points. The cells were pre-
treated with five different pharmacological inhibitors before they were exposed to the 
fluorescent compounds for detailed uptake mechanism studies. After exposure for required 
period of time with the fluorescent compounds, the cells were then washed,  fixed with 4% 
paraformaldehyde and washed three times (300 × g, 10 min, 4°C) with ice cold PBS. 1 × 106 
fixed cell suspensions were transferred into fluorescence-activated cell sorter (FACS) tubes 
and centrifuged (750 × g, 4°C, 10 min). The cell pellets were resuspended in 1 ml buffer 
(0.1% sodium azide, 2.5% FCS in PBS) and washed again in 1 ml buffer. The pellet was then 
finally resuspended in 300 μl of the buffer for measurement and 20,000 total events were 
acquired per sample.  
Similarly, the fluorescence intensity of promastigotes treated with propidium iodide 
(PI) and YO-PRO®-1 dyes (Life Technologies, Darmstadt, Germany) were measured by flow 
cytomtery as indicators for membrane integrity123. L. major promastigotes were treated with 2 
μM PHMB for various time points and then washed at 3,000 × g for 10 min. The 
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promastigotes were stained by incubating with PI or YO-PRO®-1 dyes for 15 min in the dark 
at room temperature (RT) according to manufacturer’s instructions. The dyes can enter and 
stain the parasite only after loss of membrane integrity. The promastigotes were then washed 
with FACS buffer and a total of 100,000 total events were immediately acquired by the flow 
cytometry. The MACS Quant Analyzer (Miltenyi Biotec, Bergisch Gladbach, Germany) 
based on the same instrument setting for all measurements were used. The data were analyzed 
using FlowJo software (Tree Star Inc., CA, USA).  
3.4 Transmission electron microscopy 
To investigate the uptake mechanisms of NPs, the BMDM, L929 or 293T kidney epithelial 
cells were allowed to take up polystyrene NPs at different time points. The cells were then 
harvested from culture plate, transferred to 15 ml polypropylene tube and washed with PBS at 
300 × g, 4 °C for 10 min. The cells were fixed by incubating with 1 ml of 2.5% buffered 0.2 
M cacodylate in glutaraldehyde at 4°C overnight. At the next day, the cells were washed five 
times (300 × g, 5 min at RT) in 0.5 ml of 50 mM cacodylate buffer (pH 7.2) while incubating 
at RT for 3 min in between each washing step. The cells were further treated with 0.2 ml of 
2% buffered OsO4 containing 25% H2O, 25% 0.2 M cacodylate and 50% OsO4 at 4°C 
overnight for further fixation. The cells were then similarly washed five times in 0.5 ml of 
H2O (1200 × g, RT, 5 min). The cells were further incubated with 0.1 ml of 0.5% aqueous 
uranyl acetate (Sigma-Aldrich) overnight at 4°C for contrast and nucleus staining. The cells 
were again washed five times in 0.5 ml of H2O while incubating at RT for 3 min in between 
each washing step.  
After successful fixation steps, the cells were dehydrated by incubating and washing in 
various ethanol concentration. Briefly, the cells were incubated in 0.5 ml of 50% ethanol 
concentrations for 30 min at 4°C before washing at 1200 × g, 4°C for 5 min. This dehydration 
step was repeated for each 70%, 90%, 96% and 100% ethanol concentrations, respectively. 
38 
 
The cells were again incubated in 0.5 ml of 100% ethanol concentrations for 30 min at RT. 
They were then incubated in 0.5 ml readymade 100% propylene oxide at RT for 30 min and 
washed at 1200 × g, RT, for 5 min. Finally, the cells were incubated in 0.5 ml readymade 
100% propylene oxide at RT for 30 min and transferred to small embedding tube. Then, the 
embedding step followed by centrifuging the cell suspension at 1200 × g, RT, for 5 min and 
carefully discarding the supernatants.  Embedding was done by adding Epon 812 to propylene 
oxide at 1:1 ratio carefully without disturbing the cell sediment. The cells were incubated at 
RT overnight for evaporation of propylene oxide. After removing the mixed Epon and 
propylene oxide supernatant on the next day, the cells were embedded again in pure Epon for 
21 h at RT and allowed to polymerize at 60°C for 2 days. Note that for morphology 
characterizations of the PHMB/CpG polyplexes by TEM, all fixations, dehydration and 
embedding were not necessary but the polyplexes were directly stained with uranyl acetate 
and lead citrate for imaging. Imaging was performed after the polyplex suspension or ultrathin 
sectioned cells were mounted on 300-mesh grids, and stained with uranyl acetate and lead 
citrate. TEM (JEOL JEM-2100, Germany) at an accelerating voltage of 80 kV with 200 kV 
with TVIPS F416 4k x 4k and Olympus Veleta 2k x 2k camera systems were used. The TEM 
procedures for experiments with L. major promastigotes were the same as for the mammalian 
cells except centrifugations were performed at 3,000 × g, 10 min at RT and concentration of 
the parasites used were 107 parasites per ml. 
3.5 Luciferase reporter assay  
The virulent L. major parasites expressing the luciferase reporter gene called luciferase-
transgenic strain (Luc-tg) containing the firefly luciferase reporter gene was generated as 
previously described124. Luc-tg strain was maintained by continuous passage in female 
BALB/c mice and was grown in 96-well blood agar cultures at 27°C, 5% CO2, and 95% 
humidity. The metacyclic Luc-tg promastigotes were grown in 96-well blood agar cultures 
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and the fourth passage was used for infecting macrophages. The parasites were collected into 
a 50 ml polypropylene tube and washed twice with 20 ml of PBS at 3,000 × g, 10 min at RT. 
After suspending the parasite pellet in 2 ml of complete RPMI medium, the parasites numbers 
were adjusted to 3 × 106 parasites per ml to achieve an infection rate of macrophages to 
promastigotes (cell/parasite ratio) of 1:15. Meanwhile, BMDM were harvested and counted 
according to the described cell culture protocol. The numbers of the macrophages were then 
adjusted to 2 × 105 cells per ml and 200 μl of the cell suspension was seeded into 96-well 
plates. The plate was pre-incubated for 4 h to allow adherence of macrophages to the surface 
of the plate before the supernatant was discarded and replaced with an equal volume of 
complete RPMI medium containing 3 × 106 parasites per ml promastigotes suspension. After 
incubating (37°C, 5% CO2) for 24 h to allow full differentiation of the promastigotes into 
amastigotes, the medium containing the extracellular parasites was removed and the wells 
were washed 3-5 times with the same medium. During washing, the plates were observed 
under optical microscopy to confirm complete removal of all extracellular parasites. And 
consequently, the washing supernatant (medium) was removed from the wells and replaced by 
five serial dilutions (1:5) of each target substance in complete RPMI in duplicate. Three 
controls were used: A growth control containing complete RPMI and infected BMDM in 
triplicate, a general control comprising uninfected BMDM, equal volume of water with the 
target substance and medium in duplicate, and a color control for each substance which 
comprises the highest dilution of the target substance and complete RPMI medium only. After 
further 24 h of incubation at 37°C and 5% CO2, the infected BMDM were lysed with a 
luciferin-containing buffer (Britelite, PerkinElmer, Germany) to release the luciferase enzyme 
into solution. The free luciferase enzyme then catalyzes a reaction that generates light. Thus, 
the assay is based on bioluminescence measurement of firefly luciferase enzyme that 
catalyzes the formation of light from ATP and luciferin. The luminescence was then measured 
with a luminescence plate reader, Victor X Light 2030 luminometer (PerkinElmer). This is 
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proportional to the amount of luciferase gene expression or the number of the parasites. The 
IC50 values of the compounds against intracellular amastigotes were calculated based on the 
intercept theorem as previously described124,125.   
3.6 AlamarBlue assay 
AlamarBlue assay is a redox-sensitive assay that quantitatively measures cell viability and 
proliferation using colorimetric detection strategies. The cytotoxicity of various NPs, 
compounds and nanoformulations were assessed against mammalian cell (BMDM or 293T 
epithelial cells) as previously described126. 4 × 104 cells per well were co-cultured with five 
serial dilutions of each compound in 96-well plates at 37°C for 24 h. Similarly, 10 × 106 
virulent L. major isolate promastigotes (MHOM/IL/81/FE/BNI strain) per well were co-
incubated with five serial dilutions of each compound in 96-well plates at 27°C for 24 h.   
After the co-cultures, alamarBlue cell viability assay reagent was added to each well at 10% 
final concentration and incubated for further 48 h. The optical density (OD) was then 
measured by using Multiskan Ascent ELISA reader at a wavelength 550 nm and 630 nm. The 
OD value or % dye reduction is proportional to viable cell/parasite number and was used for 
IC50 calculation based on the intercept theorem.  
3.7 Electrophoretic mobility shift assay (EMSA) 
EMSA is used to detect complexes of polymers or proteins with nucleic acids and widely used 
for the characterization of two interacting molecules127. We used for physicochemical 
characterization of PHMB/DNA interactions (polyplexes) of different types of DNA.  
Namely, high-purity genomic DNA (gDNA) that was isolated from 1.5 × 109 L. major 
promastigotes using silica-based, microcentrifuge spin-column (Purelink® Genomic DNA kit 
K1820-01, Life Technologies, Germany) and CpG ODN with sequence 
TCCATGACGTTCCTGATGCT purchased from Eurofins MWG Operon, Germany. For 
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gDNA from the parasites, the DNA concentration and purification were assessed and 
quantified by NanoDrop 2000 spectrophotometer (Thermo Scientific, Germany). 
PHMB/gDNA complex formulations were prepared by adding and mixing 4.5 μg of gDNA 
with PHMB (0-54 μg) in a final volume of 30 μl water. After thorough mixing by pipette, the 
polyplexes were left stabilizing at RT for 2 h prior to any of the experiments. The polyplexes 
were mixed with 6× Blue/Orange loading dye (Promega, Germany)  at 4:1 sample to dye ratio 
and loaded to 1% agarose gel containing SYBR® gold nucleic acid gel stain (S11494, Life 
Technologies, Germany) for electrophoresis at 100 Volts for 3 h.  To investigate PHMB/CpG 
interactions and their physicochemical characterization, PHMB/CpG ODN and PHMB/CpG-
R polyplex formulations were prepared in the same manner by mixing 30 μg CpG ODN 1668 
or 15 μg of CpG-R with PHMB (0-54 μg) in a final volume of 30 μl water, respectively. After 
the polyplexes were stabilized for more than 20 min, the samples were then combined with 6× 
Blue/Orange loading dye (Promega, Germany) at 4:1 sample to dye ratio and loaded to 1% 
agarose gel containing SYBR® gold nucleic acid gel stain for electrophoresis at 100 Volts for 
45 min. 2-Log DNA ladder (0.1-10.0 kb, New England Biolabs) was used as a positive 
control. Intas Science Imaging gel reader (Germany) and Luminescent Image Analyzer (GE 
Healthcare Life Sciences, Imagequant LAS 4000, Germany) were used for Gel 
documentations of non-fluorescent and fluorescent molecules, respectively.  
3.8 Dynamic light scattering and electrophoretic light scattering  
Dynamic light scattering (DLS) is a well-established technique for measuring the size and size 
distribution of particles dispersed in a liquid. The Brownian motion of particles in suspension 
causes laser light to be scattered at different intensities and the intensity fluctuations yields the 
velocity, which have relationship with the particle size. Likewise, electrophoretic light 
scattering (ELS) measures the electrophoretic mobility of particles in dispersion. It is based 
on the fundamental physical principle of electrophoresis, in which an electrical field is applied 
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to the electrodes, and particles with a net charge or a net zeta potential will migrate towards 
the oppositely charged electrode with a velocity (mobility). For further characterizations of 
PHMB/CpG ODN polyplexes, particle sizes and zeta potential were measured by using a 
Beckman coulter Delsa Nano C (Beckman Coulter, Krefeld, Germany). CONTIN analysis 
mode and Smoluchowski equation were used to determine the size and the zeta potential, 
respectively. The polyplex formulations were first prepared by mixing appropriate relative 
weight ratio of PHMB/CpG ODN.  The size distributions with their polydispersity index 
(PDI) and zeta potential measurements were performed using DSL and ELS in clean 
disposable cuvettes containing 500 μl Millipore water and ISA water (KCl 0.15M), 
respectively. All measurements were carried out at 25ºC.  Scattered light was detected in an 
angle of 165° (particle size) and 15° (zeta potential). The measurements were done in 
triplicates and reproduced at least three times.  
3.9 Isothermal titration calorimetry 
Isothermal titration calorimetry (ITC) is used to study the binding behavior of biomolecules 
and is applicable in wide varieties of biomedical researches including the characterization of 
molecules mechanism of actions. The nature of interactions between PHMB and CpG ODN 
were investigated by ITC (MicroCal™ iTC200 System, GE Healthcare Northampton, MA, 
USA) by directly measuring the heat released or absorbed during binding events. The samples 
were diluted to desired concentrations in Millipore water and degassed by ultrasonication for 
15 min prior to measurements. A 40-μl microsyringe was filled with PHMB as a titrant and 
injected at a rate of 2 μl/injection into cell sample containing 200 μl CpG ODN for a total of 
20 individual injections. Different concentrations of the titrant with at least 20-fold higher 
concentration of the cell sample (CpG ODN) than the titrant (PHMB) were tested and 
optimized to have good saturation curve. During the injection and measurement, the reaction 
was facilitated by using the titrant syringe as the stirrer with the speed of 400 rpm. The 
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stabilization delay of the heat signal before the first injection was adjusted at 3 min with 150 
seconds injection interval and 5 ± 0.5 μcal/sec calibration power. The measurements were 
performed at 25°C in triplicates and all experiments were repeated three times. Background 
titrations were carried out by using identical PHMB titrant solution but the cell filled with 
Millipore water and also successive Millipore water additions to the CpG ODN solutions to 
determine the background heat to be subtracted from the main experiment. All data were 
automatically collected and analyzed using Origin® Software to get thermodynamic 
parameters associated with the interaction. The binding isotherm (ΔH) was used for fitting to 
an appropriate model.   
3.10 Fluorescence microscopy and confocal microscopy 
Localizations and colocalizations of fluorescent molecules or particles in mammalian cells 
and promastigotes were performed by a live video fluorescence and/or confocal microscopy 
imaging system (Wetzlar, Germany). In mammalian cells, the cells were harvested by either 
scraping or trypsinizing methods after incubating the culture dishes on ice for 10 min and 
washing with PBS.  The cells were transferred to 50-ml tubes and washed with 20 ml of PBS 
(300 × g, 10 min, 4°C). The supernatants were discarded and the pellet was re-suspended in 3 
ml cold RPMI. The cells were then counted in Neubauer counting chamber (0.1 mm depth) by 
making a 10-fold dilution in Trypanblue (10 µl of cells to 90 µl of Trypanblue) and the 
number of cells were adjusted to 2 × 105 cells/ml. The cells were then co-cultured with the 
molecular probes by incubating at 37°C, 5% CO2 for required time points depending on the 
time required for the uptake and attachments to bottom of culture dishes or chamber slides. 
After washing in ice-cold PBS (300 × g, 10 min, 4°C) for three times, the cells were fixed in 
4% paraformaldehyde for 10-15 min at RT and further washed with PBS. Finally, 10─20 l 
of solution containing the cells were added to slides and covered with cover slips for 
microscopic examinations. However, for chambers slide, the imaging was performed directly 
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after fixing and washing steps. For promastigotes, the procedures were similar to the 
mammalian cells as indicated above. The few exceptions are that the washings of the 
promastigotes were performed at 3,000 × g, 10 min at RT. Moreover, the concentration was 
adjusted at 3 × 106 parasites per ml and the experiments were performed in culture dishes.  
3.11 Determination of cytokine productions 
Initial recognition by the immune system is an essential determinant for the fate and 
distribution of materials inside the body100. The effect of CpG ODN on the host immune 
system and its influence on proinflammatory cytokine productions have been investigated by 
many groups. In order to investigate immune modulation property of the polyplexes compared 
to free CpG ODN or PHMB, BMDMs were generated from female BALB/c mice. The 
number of BMDM was adjusted to 2 × 106 BMDM and 0.5 ml of the volume was seeded in 
24-well plates and incubated at 37°C  for 30 min in the presence/absence of CpG ODN (1.5 
μg/ml). PHMB, CpG ODN or PHMB/CpG ODN polyplexes of various concentrations were 
prepared and added to the pre-activated or control cell wells. The plate was further incubated 
for 48 h for the production of proinflammatory cytokines. The supernatants were then 
collected from all wells and IL-6, IL-10, IL-4 or TNF-α (BD Biosciences, Wiesbaden, 
Germany) concentrations were measured by sandwich enzyme-linked immunosorbent assays 
(ELISA) while IL-12p70 was measured by using the IL-12p70 ELISA Ready-SET-Go kit 
from eBioscience according to the suppliers' instructions.  
3.12 Statistical Analysis  
Normalization and percentage calculations were done based on mean fluorescence intensity 
(MFI) of the treated cells as compared to the control in flow cytometry data analyses. The 
values are given as mean ± standard error (SE). Statistical significance was determined by 
using one sample t-test or Student's t test (Microsoft Excel Software). For quantitative 
colocalization analysis, ImageJ (freely available software) was used.  
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4. RESULTS 
4.1 Chapter one: Discovery of polyhexanide as novel antileishmanial agent 
4.1.1 Efficacy of PHMB against L. major 
To investigate its potential use as topical therapeutic agent against CL, PHMB, a widely used 
antimicrobial polymer and wound antisepsis, was tested against the extracellular form of L. 
major (promastigotes) by using AlamarBlue cell viability assay as previously described126. 
The results showed that PHMB can effectively kill the promastigotes at sub-micromolar 
concentrations in a dose-dependent manner as compared to the growth control (Fig. 3). 
 
Fig. 3. Dose-dependent antileishmanial activity of PHMB against L. major promastigotes. 
Growth inhibition was determined in vitro using an AlamarBlue assay. Miltefosine, 
pentamidine and amphotericin B were used as positive controls while distilled water was used 
as negative control (mock). The error bars show standard error of three independent 
experiments to the mean. 
 
 Determination of the 50% inhibitory concentration (IC50) results confirm that PHMB 
is active against L. major promastigotes in vitro with IC50 = 0.41 μM. Moreover, it provides 
evidence that PHMB show higher potency than the current standard antileishmanial drugs 
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used in clinics. PHMB is about 69- or 39-fold more potent than miltefosine or pentamidine, 
respectively. Surprisingly, it is more than 1,000 fold more potent than paromomycin, the 
currently recommended drug for topical treatment of CL.  It has been shown that PHMB 
eliminates Aspergillus growth starting at a dose of 4 µg/ml128, which is higher than the doses 
needed to kill L. major promastigotes. Furthermore, efficacy of PHMB was assessed against 
the intracellular form of L. major (amastigotes) in BMDM infected model. The results showed 
that the activity of PHMB against the intracellular amastigotes (IC50 = 4 μM) was equal to the 
IC50 against BMDM, suggesting no relative selectivity towards the promastigotes as 
compared to macrophages (Table 1). 
IC50= minimum concentration of the substances required to kill 50% of the population; SI = 
mean IC50 against BMDM /mean IC50 against L. major promastigotes or amastigotes; ND = 
not determined.   
Table 1. Antileishmanial efficacy of PHMB, polyplexes and standard drugs. The selectivity 
index (SI) and IC50 values against promastigotes or amastigotes as compared to standard 
antileishmanial drugs are shown. The tables are the average IC50 values of 3-6 independent 
experiments for each compound. 
 
Substances  IC50  (µM) 
promastigotes 
SI 
promastigotes 
IC50   (µM) 
amastigotes  
SI 
amastigotes 
 
PHMB  
 
0.41 ± 0.25 
 
9.75 
 
4 ± 0.65  
 
1 
 
CpG ODN 
 
>150  
 
ND 
 
>150  
 
ND 
 
PHMB/CpG (1:2 w/w) 
 
PHMB/CpG (1:1 w/w) 
  
PHMB/CpG (2:1 w/w) 
 
Paromomycin  
 
Miltefosine 
 
Pentamidine 
 
Amphotericin B 
2.54 ± 0.5 
 
2.2 ± 0.28 
 
1.45± 0.33 
 
>500 
 
28.33 ± 5.2 
 
16.19 ± 31 
 
0.42 ± 0.5 
52.7 
 
22.7 
 
22.8 
 
ND 
 
2.67 
 
7.9 
 
>50 
 
1.12 ± 0.23 
 
2. 82 ± 2.8  
 
1 ± 0.55  
 
1500 ± 12.5 
 
54 ± 8.1  
 
6.38 ± 2.4 
 
0.099 ± 0.05 
119.4 
 
17.7 
 
15.89 
 
ND 
 
1.4 
 
20 
 
>208 
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To further confirm the potency of PHMB against L. major promastigotes, the parasites 
were treated with 2 µM PHMB for 24-48 h and the samples were prepared for transmission 
electron microscopic and light microscopic examinations as compared to the untreated 
controls. Our visual examinations by light microscopy and TEM clearly showed 
morphological and behavioral changes in PHMB-treated promastigotes as compared to 
untreated parasites (Fig. 4). It confirms that PHMB has observable activity against L. major 
promastigotes.  
 
Fig. 4. Effects of PHMB on L. major morphology and behavior. (a-d) TEM images of L. 
major promastigotes (right) showing morphological changes such as shrinkage, extensive 
cytoplasmic vacuolization (V), marked loss of cytosolic contents and condensed nucleus (N). 
Images b and d were taken after treatment with 2 μM PHMB for 48 and 24 h, respectively. 
The untreated controls (left) show normal elongated morphology of promastigotes with intact 
and clear distinct kinetoplast (kDNA), N, mitochondrion (M), lipid vacuoles (LV) and 
glycosome (G). (e-h) Light microscopy images showing morphological and behavioral 
changes (no more clamp formation as indicated by arrowheads) after treatment with 2 µM 
PHMB for 24 h. Scale bars = (a) 1.1 µm, (b) 0.6 µm, (c and d) 0.25 µm, (e and f) 7.5 µm and 
(g and h) 25 µm.   
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   Promastigotes plus water              Promstigotes plus PHMB 
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To determine the level of host/pathogen selectivity of PHMB, we measured its 
cytotoxicity against BMDM and 293T epithelial cells using the AlamarBlue assay. 
Surprisingly, the IC50 value obtained indicate that PHMB is about 6.5-fold more toxic against 
BMDM (IC50 = 4 μM) than 293T epithelial cells (IC50 = 26 μM), resulting in selectivity 
indexes (SI) of 9.75 and 63.4 against these cell types, respectively (Table 2). The results show 
that the toxicity of PHMB is different in different host cell types. We speculate that 
phagocytic cells such as macrophages take up more PHMB than 293T epithelial cells, which 
may consequently result in higher toxicity.  
Substances  IC50  against  BMDM 
(µM) 
IC50   293T 
epithelial cells (µM) 
   
PHMB 4± 0.65 26 ± 6.8 
PHMB/CpG (2:3) 
 
196 ± 80 ND 
PHMB/CpG (1:2) 
 
134 ± 40.2 ND 
PHMB/CpG (1:1) 
 
50 ± 10.4 185± 22.5 
 
PHMB/CpG (2:1) 
 
33± 9.5 
 
90.3± 23.5 
Paromomycin  
 
>1500 ND 
Miltefosine 
 
75.6 ± 6.5 ND 
Pentamidine 
 
127.9 ± 23.2 ND 
Amphotericin B 
 
>21 ND 
 
The concentration given to the polyplexes represents the concentration of PHMB 
ND= not determined.   
Table 2. Cytotoxicity effects of PHMB and PHMB/DNA polyplexes as compared to standard 
antileishmanial drugs. The table shows cytotoxicity of each compound. The IC50 values of 
each compound against BMDM and 293T epithelial cell line are shown. The tables are the 
average IC50 values of 3-6 independent experiments for each compound.  
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4.1.2  Uptake mechanisms of PHMB by BMDM and its proposed mechanisms of action 
against L. major 
After determining the potency and selectivity of PHMB against L. major promastigotes, we 
were interested to know its underlying mechanism of action. To have a clue where to start, we 
reviewed literature on PHMB’s mechanisms of action against other microbes. It suggested 
that PHMB’s microbe-selective toxicity is due to preferential disruption of microbial 
membranes rather than mammalian membranes121,129. We then hypothesized that PHMB kills 
L. major parasites by this mechanism. Two plasma membrane permeability markers were 
used to test the effects of PHMB on the membrane integrity of the promastigotes. PI, a dye 
that can enter the parasite and stain DNA only after loss of membrane integrity, and YO-
PRO®-1 dye, another plasma membrane permeability marker which selectively passes 
through the plasma membranes of apoptotic cells but it does not label living cells123. After 
incubating the promastigotes with 2 μM PHMB for only 30 min, more than 20% of the 
parasite population was stained by PI and the staining increased at later time points (Fig. 5a). 
This dye exclusion experiment was repeated by using YO-PRO®-1 dye according to the 
manufacturer’s instructions. The results similarly showed time-dependent permeabilisation of 
the parasite even at early time points (Fig. 5b). Taken together, the dye exclusion assay results 
clearly show that PHMB damages the membrane integrity of the parasite in a time-dependent 
manner. Moreover, as it can be clearly seen from the figure (Fig. 5), it shows that 
permeabilized parasites can be observed within 30 minutes of PHMB treatments, supporting 
the hypothesis that PHMB disrupts parasite membranes.  
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Fig. 5. Time-dependent effect of PHMB on membrane integrity of L. major promastigotes.  
Representative detailed FACS data of (a) PI and (b) YO-PRO®-1dye staining of 
promastigotes after treatment with 2 µM PHMB for indicated time points, showing time-
dependent effect of PHMB on the membrane. Amphotericin B at 2 µM concentration and hat 
killed promastigotes were used as positive control. 
Furthermore, we consistently observed condensation of parasite nuclei after incubation 
with 2 μM PHMB for 24─48 h in our TEM pictures (Fig. 4). In line with this observation, 
PHMB’s mechanism of bactericidal action was associated with its strong and cooperative 
interaction with all forms of nucleic acids in vitro130. These observations led us to consider 
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that killing mechanisms of PHMB may be more complex, and we further investigated whether 
PHMB also targets DNA inside parasites. Cellular DNA of L. major promastigotes was 
stained with Hoechst 33342 after treated with 2 μM PHMB for 48 h. Confocal and 
fluorescence microscopy study results show that PHMB condenses and disrupts chromosome 
structures in the parasites (Fig. 6).  
 
Fig. 6. Fluorescent microscopy analysis showing condensed and damaged DNA materials of 
L. major promastigotes after treatment with PHMB. The concentration of PHMB used was 2 
μM for 48 h while the mock control was distilled water.  
 
 We further confirmed our observation of PHMB effects on DNA materials of the 
parasites by supposing that if the observations are correct, then it should also bind isolated 
parasite genomic DNA (gDNA). To test this hypothesis, genomic DNA of L. major 
promastigotes was isolated from 1.5 × 109 parasites using Purelink® Genomic DNA kit 
(K1820-01, Life Technologies, Germany) and was quantified by using a NanoDrop 2000 
spectrophotometer (Thermo Scientific, Germany). PHMB/gDNA polyplex formulations were 
prepared and electrophoretic mobility shift assay (EMSA) was performed. The results 
confirmed that PHMB has an excellent binding affinity towards isolated genomic DNA and 
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forms PHMB/gDNA polyplexes at relative weight ratios ≥ 0.25, confirming that PHMB can 
bind gDNA from parasites, and, thus, may also bind chromosomal DNA within parasites (Fig. 
7).  
 
Fig. 7. Formation of PHMB/gDNA polyplexes as confirmed by 1% agarose gel, showing 
PHMB/gDNA interactions. With the exceptions of negative control and PHMB alone, all 
wells contained equal amounts (weight) of DNA with various concentrations of PHMB. M 
represents 2-Log DNA ladder (0.1-10.0 kb, New England Biolabs) and N represents water for 
negative control. All indicated PHMB/gDNA ratios are in relative (w/w). 
 
We next asked a question that if the mechanisms of action of PHMB against L. major 
promastigotes involve DNA binding and disruption, how it selectively condenses or disrupts 
only the chromosomes of the parasites without affecting the DNA of the mammalian host 
cells. To address this question, PHMB-FITC was produced by covalent conjugation of PHMB 
with fluorescein isothiocyanate (FITC). First, we then investigated the uptake properties of 
PHMB-FITC into L. major and macrophages, and checked where it localizes. For this 
purpose, BMDM cells were incubated with 1 μM PHMB-FITC, counterstained with Hoechst 
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33342, and internalization was investigated using confocal microscopy. The results confirmed 
that PHMB-FITC is readily taken up by macrophages (Fig. 8). However, PHMB-FITC 
exclusively localized in the cytoplasm without entering nuclei in mammalian cells, indicating 
failure to transit across the nuclear envelope (Fig. 8). 
 
Fig. 8. Cell localization of PHMB-FITC in BMDM. Laser scanning confocal images showing 
uptake of PHMB-FITC by BMDM (lower) and control cells (upper). Note apparent nuclear 
exclusion in BMDM cells, scale bars = 10 µm. 
In the same manner, BMDMs were incubated with 1 μM PHMB-FITC, washed three 
times with PBS (300 × g, 10 min, 4°C) and uptake was quantified by flow cytometry. The 
results revealed that about 100% of the macrophages accumulate enough PHMB-FITC that 
could be detected by flow cytometry as early as 1 h, indicating their ability to entry into 
BMDM. Moreover, the results also showed that BMDM take up PHMB-FITC in a time-
dependent manner (Fig. 9a).  BMDM cells were also incubated with 1 μM PHMB-FITC/CpG 
ODN polyplexes for different time points and intracellular intensity was quantified by flow 
cytometry. The results show that the cellular uptake of PHMB-FITC/CpG ODN polyplexes is 
time-dependent (Fig. 9b). 
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Fig. 9. Time-dependent cellular uptake of PHMB-FITC and PHMB-FITC/CpG ODN 
polyplexes by BMDM. The representative flow cytometric data show uptake of (a) PHMB-
FITC and (b) HMB-FITC/CpG ODN polyplexes into macrophages, and the histograms show 
the overlay of their uptake at 0 h, 30 min, 4 h and 12 h. 
Similarly, L. major promastigotes were incubated with 0.35 μM fluorescent PHMB 
(sub-IC50) to investigate whether they take up PHMB-FITC or not. Our results confirm that L. 
major parasites take up PHMB-FITC without apparent exclusion from their nucleus (Fig. 10). 
Therefore, the intracellular localization of PHMB appears to differ in BMDM and parasites, 
with PHMB gaining access to parasite chromosomes. 
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Fig. 10. Localizations of PHMB-FITC in promastigotes. Fluorescence microscopy images showing uptake of PHMB-FITC by promastigotes (lower) 
and control cells (upper). Note no apparent nuclear exclusion in the parasites, scale bars = 5 µm. 
Understanding the uptake mechanisms of PHMB into macrophages is very important 
to control its intracellular antileishmanial activity and toxicity. We showed that PHMB-FITC 
was readily taken up and localizes in the cytoplasm of macrophages; however, we did not 
know the mechanism(s) of how BMDM take up PHMB. To address this question, different 
approaches were employed. First, we checked whether the uptake of PHMB-FITC was 
energy-dependent or not. BMDMs were treated with PHMB-FITC and incubated at 4°C under 
equivalent cell culture conditions for 4 h. The uptake of PHMB was then quantified by flow 
cytometry after washing three times with PBS, fixation with 4% paraformaldehyde and 
further washing with PBS. The results showed that the uptake of PHMB was strongly reduced 
(87%) at 4°C as compared to incubating the cells at normal 37°C (Fig. 11). This indicates that 
the predominant uptake mechanism of PHMB-FITC by BMDM is an energy-dependent 
cellular process or endocytosis but not energy-independent pathways such as direct 
penetration or diffusion. To further know the specific endocytosis pathway(s) involved in the 
uptake, five different selective endocytosis inhibitors were employed, as recently described122. 
These includes wortmannin, a potent inhibitor of phosphatidylinositol kinase (PI3K) that is 
commonly used as inhibitor of macropinocytosis at a dose of 12.85 μg/ml, cytochalasin D, a 
commonly used inhibitor of phagocytosis by blocking the actin polymerization at a dose of 5 
μg/ml, dynasore, a cell-permeable small molecule that inhibits dynamin GTPase activity 
needed for dynamin-dependent endocytosis at a dose of 25.8 μg/ml, chlorpromazine 
hydrochloride that inhibits a Rho GTPase which is essential for the formation of clathrin-
coated vesicles in clathrin-dependent endocytosis at dose of 10 μg/ml, and ikarugamycin, an 
inhibitor of clathrin coated pit-mediated endocytosis at a dose of 1 μM . Moreover, alexa-448-
labeled transferrin and FITC-labeled dextran were used as positive control for clathrin-
dependent endocytosis and to exclude the effect of FITC that might interfere with the cellular 
uptake mechanisms of PHMB, respectively. BMDMs were pre-incubated with each of the 
five specific endocytosis inhibitors for 30 min and exposed to PHMB-FITC, dextran or 
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transferrin followed by incubation at 37°C for 4 h. The results show that only dynasore 
effectively inhibited the uptake of PHMB-FITC (80% inhibition), showing that the PHMB-
FITC uptake mechanism is dynamin-dependent endocytosis (Fig. 11). Similar results were 
obtained for PHMB-FITC/CpG ODN and PHMB/CpG-R polyplexes (Figs. 11 and 12), 
suggesting the uptake pathways of PHMB by BMDM was not affected by a polyplex 
formation process. However, neither the uptake of alexa-448-labeled transferrin or FITC-
labeled dextran by BMDM was inhibited by equal concentrations of dynasore. Taken 
together, the data shows that the uptake mechanism of PHMB is predominantly via dynamin-
dependent endocytosis rather than other endocytosis pathways.  Moreover, the data confirmed 
that dynasore effectively blocks the uptake of PHMB or its polyplexes into macrophages. 
 
Fig. 11. Cellular uptake mechanisms of PHMB-FITC and PHMB-FITC/CpG ODN polyplexes 
based on effects of selective endocytosis inhibitors. The bar graphs show the effects of 
different inhibitors and temperature on cellular uptake of (a) PHMB-FITC, (b) PHMB-
FITC/CpG ODN polyplexes, (c) dextran/FITC and (d) alexa-448-labeled transferrin used as 
positive controls. Normalized mean fluorescence intensity (MFI) values of three independent 
flow cytometry experiments are shown and the values are given as mean ± SE.  
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Fig. 12. Uptake mechanism(s) of PHMB/CpG polyplexes and CpG ODN delivery into 
macrophages. The cellular uptake potential of (a) PHMB/CpG-R and (b) PHMB-FITC/CpG 
ODN polyplexes, and inhibition by dynasore. Free PHMB-FITC, PHMB-FITC/CpG ODN 
and PHMB/CpG-R polyplexes were efficiently blocked by dynasore. Based on their MFI, the 
uptake of CpG-R was enhanced by about 15 folds as polyplex form compared to its free form.  
We next hypothesized that if dynasore inhibited the uptake of PHMB or its polyplexes, 
it should also suppress PHMB’s intracellular killing of amastigotes. To test this hypothesis, 
we determined the efficacy of PHMB or its polyplexes against intracellular amastigotes using 
luciferase reporter assay in the presence/absence of dynasore (80 µM). The results show 
clearly that dynasore inhibits PHMB-mediated killing of amastigotes (Table 3). In the 
presence of dynasore (80 µM), the IC50 value of PHMB against the intracellular amastigotes 
was increased twice and the polyplexes were completely inactive until the maximum dose 
tested (14.2 µM), while the activity of PHMB and the polyplexes were enhanced against the 
promastigotes in the presence of dynasore (80 µM). Dynasore alone didn’t show any 
cytotoxicity against both amastigotes and promastigotes. The result suggests that dynasore 
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rescued the parasites from the intracellular antileishmanial effects of PHMB by blocking 
polymer uptake into host cells. The results also confirm our earlier evidence for PHMB 
intracellular killing of amastigotes. 
Substances IC50  (µM) 
amastigotes  
IC50  (µM) 
amastigotes + 
dynasore  
IC50  (µM) 
promastigotes  
IC50  (µM) 
promastigotes +  
dynasore  
PHMB 4 ± 0.7 8.1 ± 2  0.41 ± 0.25 0.114 ± 0.15  
PHMB/CpG (1:2) 
 
1.12 ± 0.23 >14.2 2.54 ± 0.5 0.11 ± 0.53 
PHMB/CpG (1:1) 
 
2.82 ± 2.8 >14.2 2. 2 ± 0.28 0.21 ± 0.14 
PHMB/CpG (2:1) 
 
Dynasore (80 
µM) 
1 ± 0.6  
 
No activity 
>14.2 
 
No activity 
1.45 ± 0.33  
 
No activity 
0.14 ± 0.23 
 
No activity 
     
The concentration values given are for PHMB with polyplexes. 
 
 Table 3. Dynasore rescues killing of L. major amastigotes inside macrophages. The table 
shows that dynasore inhibits killing of the intracellular L. major amastigotes by PHMB or 
PHMB/CpG ODN polyplexes through blocking their uptake into macrophages. However, the 
dynasore enhanced the antileishmanial effects PHMB and the polyplexes against 
promastigotes. The table shows summary result of two independent experiments and the 
values are given as mean ± SE. 
 
It was then important to analyze whether the internalized PHMB were localized into 
endosomes of BMDM. We used the most common lysosomotropic agent called chloroquine 
to rupture endosomes131.  Rupturing endosomes by chloroquine showed increased mean 
fluorescence intensity of PHMB-FITC inside BMDM in dose dependent manner, suggesting 
their localizations in endosomes (Fig. 13). At 150 µM chloroquine concentrations, the uptake 
of PHMB-FITC by BMDM was increased by about 27%. We speculate that PHMB are 
rapidly internalized by BMDM and accumulate in acidic vesicles during their trafficking in 
the endolysosomal cascade. It has been shown that degradation of PHMB could be observed 
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both in acidic and alkaline conditions (5.2% and 9.4%), while temperature caused no 
degradation132.  
 
Fig. 13. PHMB-FITC localizations in the endosomes of BMDM as confirmed by increments 
of MFI after treatment with different concentrations of chloroquine. The error bars represent 
standard error of three independent experiments.  
 
4.2 Chapter two:  Understanding the interactions between nanoparticles and host 
cells 
4.2.1 Cellular uptake mechanism of polystyrene NPs based on endosomomal markers 
The drug loaded NPs have to overcome a number of transport barriers to reach at and readily 
taken up by the specific cells. In order to select and load NPs with various antileishmanial 
drugs for effective drug delivery systems against CL, understanding the cellular interactions 
and uptake mechanisms of NPs into mammalian cells is a pre-requisite. The type of laboratory 
techniques applied, the variability in fluorescence of some NPs used for tracking, the lack of 
uniformity in their physicochemical properties and the toxic nature of some NPs contribute to 
the complexity and controversial findings regarding the specific endocytic route involved in 
the cellular uptake of NPs14. To avoid such limitations, we used noncytotoxic and 
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standardized commercial polystyrene NPs which are suitable for quantitative cellular uptake 
studies and were previously used as model NPs for cellular uptake mechanism studies18. We 
aimed at systematical investigation of cellular uptake mechanisms NPs and exploring the 
factors affecting their cellular uptake in different host cells. Thus, fluorescent polystyrene 
latex beads (NPs) of different sizes (0.02 μm, 0.1 μm, 0.2 μm, 0.5 μm, 1 μm and 2 μm) were 
used to follow their uptake mechanisms in BMDM.  According to the supplier’s information, 
the polystyrene NPs were prepared though polymerization reaction with styrene that 
terminates with a carboxyl moiety and were used without any further modification. The 
diameters of the NPs were measured by TEM and were shown to be spherical NPs. To create 
intensely fluorescent signals that show little photo bleaching, polystyrene NPs were loaded 
with fluorescent dyes by physical absorption. Unlike covalently incorporating dye to NPs, 
physically absorption methods may potentially create problems such as dye aggregation and 
leakage. Thus, we initially checked whether the dye is stably retained in the polystyrene NPs 
without leakage by incubating 100 nm fluorescent NPs with BMDM at 37°C and observing 
under confocal microscopy. There was no indication for dye leakage and the polystyrene NPs 
were highly fluorescent with a distinct localization inside the cells, suggesting that this 
particular dye seems to be stably retained in the polystyrene NPs (Fig. 14). The free dye 
distribution throughout the cytoplasm as a result of diffusion across cells seems to be very 
little. The dye is largely hydrophobic, well dispersed and retained within the hydrophobic 
polystyrene matrix when the beads are kept in an aqueous solution. The fluorescent 
polystyrene NPs are also widely used as a model for NPs-cell interaction studies.  
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Fig. 14: Confocal microscopy image showing a distinct localization of highly fluorescent 
polystyrene NPs inside BMDMs, indicating no or little indication for dye leakage. The images 
were taken after BMDMs were incubated with 100 nm fluorescent polystyrene NPs at 37°C 
and 5% CO2 for 30 min and washed three times in PBS. 
  
We then assessed the cytotoxicity of the polystyrene NPs towards host cells by using 
the alamar Blue cell viability assay. The beads were sonicated (Bandelin Sonorex Super RK 
106, Berlin, Germany) for 10 min immediately prior to every experiment and were used at a 
1:1000 v/v dilution. The results showed that the polystyrene NPs were not toxic even at a 10 
times higher concentration (1:100 v/v dilutions) than the one used in the experiment (Fig. 15)  
 
Fig. 15. Cytotoxicity assessments of different size polystyrene NPs at 1:100 v/v dilutions 
against BMDM based on alamarBlue cell viability assay. The error bars represent SE of two 
independent experiments. Bank I is control containing the highest dilution of the compounds 
without cells, while, Blank II is control containing water and cells without any compound. 
Growth control contains BMDMs and medium without any polystyrene NPs.  
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Next, we investigated the cellular uptake mechanisms the polystyrene NPs by labeling 
with endocytosis marker FM4-64FX133. FM4-64FX dye stains the plasma membrane by 
becoming inserted and anchored in the outer leaflet of the plasma membrane lipid bilayer. 
Only after internalization, the dye becomes localized to the inner leaflet of endocytic vesicles. 
To this end, BMDMs were incubated with the NPs and 10 µM FM4-64FX for 30 min in 
phenol-free complete RPMI. The imaging was performed after the cells were harvested, 
washed three times with PBS and fixed with 4% paraformaldehyde. Under fluorescence 
microscopy, we observed co-localizations of FM4-64FX with the NPs inside the cells (Fig. 
16A-D). The co-localizations of the NPs and FM4-64FX dye indicate internalization via a 
shared mechanism and suggested endocytosis to be responsible for the uptake of the 
polystyrene NPs. The results obtained by using the other polystyrene NPs sizes were similar. 
Moreover, the co-localization result may also indicate intracellular localization. 
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Fig. 16. Fluorescence microscopy images of BMDMs after 30 min of incubation with 20 nm 
(A-D) NPs showing co-localization with the endosomal marker FM4-64FX. Images (E-P) are 
negative control cells treated with only the NPs, FM4-64FX or BMDM, respectively. Bright 
field (A, E, I and M), the NPs (B, F, J and N), endosomal marker FM4-64FX (C, G, K and O), 
and merge of the channels (D, H, L and P) are depicted.  
4.2.2 The uptake mechanisms of polystyrene NPs based on effects of energy 
Endocytosis is an energy-dependent cellular process. In order to confirm that the NPs uptake 
was an active process and depends on energy, BMDM were generated and treated with 20 nm 
or 100 nm NPs for different time points. The plates were incubated either at the physiological 
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temperature of 37°C in incubator or at 4°C in fridge. After fixation with 4% 
paraformaldehyde and three times washing with PBS, the NPs uptake was quantified by flow 
cytometry. After acquiring 20,000 total events, the percentages of uptake were then calculated 
based on the relative MFI of cells kept at 4°C versus cells kept at 37°C for each time point. 
For normalization purposes and clarity, the MFI values of cells kept with the NPs at 37°C for 
24 h were set as 100% and then compared with the other cells kept at both temperatures. The 
results of the flow cytometric analyses showed a time- and energy-dependent cellular uptake 
of the NPs under equivalent cell culture conditions (Fig. 17). With increasing time of 
exposure to the NPs, the normalized MFI of the cells were increasing from 8.48% at 30 min to 
100% at 24 h, showing a time-dependent intracellular accumulation. 
 
Fig. 17. Flow cytometric analyses of the effects of temperature and time on the uptake of 20 
nm and 100 nm polystyrene NPs by BMDMs. Cells were pre-incubated on ice for 10 min 
before exposure to NPs followed by incubation at 4°C for further 30 min, 4 h, 12 h or 24 h 
while the control groups of cells were incubated at 37°C for the respective time points 
throughout the incubation period. Normalized MFI values of three to six independent 
experiments are shown and the values are given as mean ± SE. 
 
 To further confirm the time-dependent accumulation of NPs inside BMDMs, 
fluorescence microscopy and TEM studies were performed. The results clearly showed time-
dependent uptake of the NPs inside BMDMs (Fig.18). Nevertheless, incubating the BMDMs 
with the same dose and batch of polystyrene NPs at 4°C under equivalent cell culture 
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conditions resulted in a strong reduction of uptake at all considered time points (Figs. 17 and 
19). It indicates that at low energy, only limited amount of polystyrene NPs are taken up by 
cells. Since there is no exocytosis expected at 4°C, we can conclude that the limited 
accumulations of NPs in cells were as a result of reduced uptake. Thus, the NP uptake is an 
active process and strongly temperature- and time-dependent. Moreover, regardless of the 
incubation period, we observed low intracellular fluorescence (about 5%) among cells kept at 
4°C (Fig. 17). Likewise, fluorescence microscopy images show similar limited uptake at 4°C 
at all time points (Fig. 19). The uptake study results for both 20 nm and 100 nm NP sizes were 
similar (Fig. 17). All together, the results confirm that BMDMs take up polystyrene NPs via 
endocytosis.  
 
Fig. 18. A representative fluorescence microscopy and TEM pictures showing time-dependent 
accumulations of 100 nm polystyrene NPs in BMDMs. Time-dependent differences in relative 
accumulation of the NPs after incubation with BMDM for 30 min (A1, A2 and E), 6 h (B1, B2 
and F) and 12 h (C1, C2 and G) can be observed. The green channel A2, B2 or C2 shows the 
polystyrene NPs while A1, B1 or C1 represents the bright field. D shows negative control 
BMDM and the white particle structures in the TEM images are the polystyrene NPs.  
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Fig. 19. Fluorescence microscopy images showing the effect of temperature and time on the 
uptake of 20 nm polystyrene NPs by BMDMs. The relative uptake of NPs increased in a time 
dependent manner at 37°C while it was strongly reduced at 4°C. For cells incubated at 4°C, 
the time difference seemed to have no effect. Bright field and the NPs (green) for each 
temperature and time point are depicted. The pictures are representatives of three 
independent experiments 
 
4.2.3  Ultrastructural analyses of membrane morphology reveal multiple cellular uptake 
mechanisms 
To further confirm endocytosis as uptake mechanism of the polystyrene NPs and investigate 
the specific routes underlying endocytosis, TEM ultrastructural studies were performed. As 
macrophages take up extracellular material by a wide range of mechanisms and thus allowed 
us to study the cellular uptake of NPs via a variety of possible entry routes, BMDMs were 
used. Macrophages are also an important drug targets as they mediate a wide variety of 
infectious diseases.  BMDMs were exposed to 100 nm polystyrene NPs for 30 min and were 
prepared for TEM study. The TEM data analyses showed that the NPs are accumulated in 
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membrane-bound intracellular vesicles as early as 30 min, confirming the involvement of 
endocytosis in NP uptake (Fig. 20 indicated by EN). The ultrastructural plasma membrane 
invaginations and protrusions also confirmed that the uptake of 100 nm polystyrene NPs by 
BMDMs were via endocytosis (Fig. 20A-E). However, a few particles were seen freely 
localized in the cytoplasm of BMDMs without membrane-bounded. Since the harsh TEM 
sample preparation processes may affect the membrane surrounding polystyrene NPs and 
make them fragile, the free localization inside the cytoplasm may not necessarily show the 
reality. Moreover, due to the level/position of the cell sectioning, it may also difficult to see 
the membranes surrounding some NPs. Thus, the observation of free NPs in the cytoplasm 
may not necessarily suggest the involvement non-endocytic uptake mechanisms. 
Moreover, we wanted to investigate whether a single cell type employs several uptake 
mechanisms simultaneously to internalize a given type of NPs. Thus, the ultrastructural 
morphology of nascent endocytic intermediates were further analyzed to know the specific 
endocytosis pathway(s) involved in the uptake of 100 nm polystyrene NPs. It appears that 
different numbers of polystyrene NPs were partially surrounded by plasma membranes 
invaginations or protrusions forming distinct ultrastructures around the surface of BMDM. 
These distinct ultrastructures are not seems to be a simple NPs attachment to surface of the 
cell membrane because we could not observe such NPs containing cell membrane structures 
throughout the cell membrane surface but localized in particular places. Indeed, by having a 
closer look at the membrane surface, the coat structures of holding the polystyrene NPs are 
also observable in some routes (Fig. 20A). Similarly, it has been also documented that the 
ultrastructural morphology of membrane invaginations and protrusions provides basic criteria 
for the identification of different endocytic pathways involved in the internalization processes 
90,91,134. Based on such plasma membrane morphology, our TEM results showed that the 
polystyrene NPs are internalized by BMDMs via multiple endocytic routes simultaneously 
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(Fig. 20A-E). These include the ultrastructure in Fig. 20B, the cell surface membrane 
deformations forming cup-like structures by trying to encircle the polystyrene NPs suggests 
early process of phagocytosis. Similarly, the ultrastrucure in Fig. 20E, plasma membrane 
protrusions or ruffles that collapse onto and fuse with the plasma membrane by trying to 
generate large endocytic vesicles indicates macropinocytosis route. The structure in Fig. 20A, 
a membrane invagination forming a more or less homogenous, symmetric polygonal lattice, 
shows early clathrin-dependent endocytosis processes. Moreover, Fig. 20D, a typical smooth 
flask-shaped morphological structure suggests an early caveolin-dependent endocytosis 
process. Fig. 20C distinct ultrastructures demonstrate other clathrin- and caveolin-independent 
pathways, routes that are characterized by polymorphous or tubulovesicular membrane 
invaginations in several entry pathways. Overall, the TEM ultrastructural analyses results 
shows BMDMs internalizes 100 nm polystyrene NPs via multiple endocytic routes 
simultaneously.  
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Fig. 20. Multiple endocytic pathways used simultaneously by BMDMs for uptake of 100 nm 
polystyrene NPs. Based on the ultrastructural morphology of plasma membrane 
invaginations/protrusions, clathrin-mediated endocytosis (A), phagocytosis (B), clathrin- and 
caveolae-independent endocytotic pathways (C), caveolae-mediated endocytosis (D), and 
macropinocytosis (E) are indicated. Intracellular vesicles containing the endocytosed NPs 
(EN), localization of the NPs in early endosomes (EL) and the nucleus (N) are also shown. 
Labeled structures (A-E) are the zoomed out portions of the depicted cell for clarity. 
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4.2.4 The ultrastructural morphology of endosomes reveals multiple cellular uptake 
pathways 
The criteria for defining specific endocytic pathways are not yet completely identified. 
However, it has been suggested that the ultrastructural morphology of endosomes containing 
NPs may reveal the type of endocytosis involved in the uptake of a given type of NPs88,135. To 
further support our observation of multiple uptake pathways based on the ultrastructural 
morphology of nascent endocytic intermediates at the plasma membrane, the size and 
morphology of the endosomes containing NP(s) were analyzed. The result showed that the 
size and morphology of endosomes containing NPs seems to be correlated with the size and 
morphology of nascent endocytic intermediates at the plasma membrane (Fig. 21). For 
instance, the morphology of  endosomes formed by clathrin- and caveolin-independent uptake 
pathways seem to maintain the tubulovesicular structure of the nascent endocytic 
intermediates at the plasma membrane (Fig. 21E and F). Similarly, the morphology of 
endosomes formed by caveolae-dependent endocytosis seems to conserve the well-defined 
flask shape of nascent endocytic intermediates (Fig. 21D). Larger endosomes (Fig. 21B) are 
associated with macropinocytosis/phagocytosis rather than other smaller size pathways like 
caveolae- or clathrin-dependent endocytosis. Since the larger size endosomes were observed 
only after 30 min incubation time, it is less likely that the larger size endosome are as a result 
of fusion of different endosomes. Furthermore, we also observed endosomes having similar 
morphology or size but contains different number of NPs (Figure 21E and F). This may 
suggest that the morphology and size of the endosomes containing the NPs is not necessarily 
adopted in accordance to the number of NPs they may contain. It suggests that the 
morphology of each endosome varies not only based on the number of NPs they contained but 
also the type of uptake routes. This may further suggest that the distinct ultrastructural 
morphology of nascent endocytic intermediates corresponds to the distinct uptake routes. 
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Thus, the ultrastructural morphology of endocytic vesicles containing NPs may give a clue 
about the uptake mechanism of NPs. Consequently, it further supports the notion that BMDM 
use multiple internalization pathways for 100 nm polystyrene NP(s). 
 
Fig. 21. Multiple uptake pathways based on ultrastructural morphology of endocytic vesicles.  
The endosomes contains 100 nm polystyrene NP(s) immediately after their internalization by 
BMDMs. The cells were fixed for TEM after 30 min of incubation with NPs. The arrows 
indicate endosomes from NPs untreated cell (A), phagosomes or macropinosomes from NPs 
treated cell (B), endosomes of clathrin-mediated endocytosis from NPs treated cell (C), 
endosomes of caveolae-mediated endocytosis from NPs treated cell (D) and endosomes of 
clathrin-and caveolae-independent endocytotic pathways from NPs treated cell (E and F). 
4.2.5 Analysis of functionally distinct uptake routes by using inhibitors to block different 
endocytic pathways 
To complement the TEM ultrastructural studies of distinct endocytosis pathways involved in 
the cellular uptake of polystyrene NPs, pharmacological inhibitors of various endocytic 
processes were employed. We used safe drug concentrations described in previous 
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studies97,99,136,137 in order to be sure  that the endocytosis inhibitions are due to the 
pharmacological effect of the inhibitors rather than their toxicity against the host cell. The 
cytotoxicity of the selected drug concentrations were further tested with BMDMs by using the 
alamarBue cell viability assay. The safe concentrations of the inhibitors with relatively high 
inhibition rates in our system were then used for blocking studies. The inhibitors used include 
wortmannin (12.85 μg/ml), a potent inhibitor of phosphatidylinositol kinase (PI3K) involved 
in different endocytic pathways but commonly used as inhibitor of phagocytosis and 
macropinocytosis135,138,139, cytochalasin D (5 μg/ml) which blocks the actin polymerization 
that participates in a variety of endocytic processes but is commonly used as inhibitor of 
phagocytosis and macropinocytosis88, dynasore (25.8 μg/ml), a cell-permeable small molecule 
that inhibits dynamin GTPase activity needed for several mechanisms including clathrin-
dependent endocytosis140,141, chlorpromazine hydrochloride (10 μg/ml) that inhibits a Rho 
GTPase which is essential for the formation of clathrin-coated vesicles in clathrin-dependent 
endocytosis88,136 and ikarugamycin (1 μM), an inhibitor of clathrin coated pit-mediated 
endocytosis137. The BMDMs, L929 fibroblasts, and 293T epithelial cells were cultured and 
exposed to 100 nm NPs in the same manner as in the TEM study described above except that 
the cells were pre-incubated with each of the five inhibitors for 30 min at 37°C. The uptake 
was measured by flow cytometry after 3 h of incubation in order to keep a balance between 
allowing sufficient time for enough NPs to enter the cells, and for the pharmacological 
inhibitors to reduce endocytosis without inducing a shift of the pathways. It has been reported 
previously that blocking one uptake pathway can result in activation of other endocytic 
mechanisms142. The results were then documented as relative uptake (percentage) based on 
MFI of inhibitor treated cells compared to untreated control cells by setting the average MFI 
of control cells without inhibitors as 100% (Fig. 22).  
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The results show that wortmannin inhibited as much as 93.7%, 70.4% and 55.3% of 
NP uptake in BMDMs, L929 fibroblasts and 293T kidney epithelial cells, respectively. Even 
though wortmannin is not as specific as other inhibitors, it showed the involvement of 
phagocytosis and/or macropinocytosis in the uptake of the NPs by all three cell types. 
Similarly, blocking actin formation by cytochalasin D reduced the NP uptake by 74.3% in 
BMDMs, 55% in L929 fibroblasts and 50.8% in 293T kidney epithelial cells. Blocking actin 
formation would inhibit macropinocytosis and phagocytosis. However, it has also been 
reported to participate in several other uptake mechanisms including clathrin-mediated 
endocytosis and caveolin-mediated endocytosis88,143. Therefore, we consider cytochalasin D 
as nonselective inhibitor of different internalization pathways, but it can point out the 
existence of macropinocytosis and/or phagocytosis pathways in this scenario again. 
Chlorpromazine, a drug considered to block clathrin-dependent endocytosis, inhibited the NP 
uptake by 77.3% in BMDMs while it only inhibited 47.5% and 42% in L929 fibroblasts and 
293T kidney epithelial cells, respectively. However, since the Rho-family GTPases are also 
involved in other pathways – such as phagocytosis and macropinocytosis93 – chlorpromazine 
cannot be regarded as specific either136. Nevertheless, it may similarly show the involvement 
of clathrin-dependent endocytosis. Furthermore, using ikarugamycin, the specific inhibitor of 
clathrin-coated pit-mediated endocytosis resulted in a 50%, 30% and 57.4% inhibition of NP 
uptake in BMDMs, L929 fibroblasts and 293T kidney epithelial cells, respectively, 
highlighting the involvement of clathrin-dependent endocytosis in these cell types. Finally, 
inhibiting dynamin-dependent endocytic pathways including clathrin-dependent endocytosis 
and caveolin-mediated endocytosis by dynasore reduced the NP uptake by similar rates in all 
the three cell types (44%, 44.5% and 45% in BMDM, L929 fibroblasts and 293T kidney 
epithelial cells, respectively). It also suggests that the remaining 55-56% of the NP uptake 
were via dynamin-independent pathways indicating that all the three cell types can use both 
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dynamin-dependent and dynamin-independent endocytic pathways for the uptake of the NPs. 
Even though it has been shown that the specificity of pharmacological inhibitors is not 
sufficient to clearly distinguish endocytic pathways136,  the findings support the TEM results 
regarding the existence and utilization of several distinct endocytic pathways by the three cell 
types for internalization of NPs.   
 
Fig. 22. Effects of different pharmacological inhibitors on the uptake of 100 nm polystyrene 
NPs by different cell types (BMDMs, L929 fibroblasts or 293T epithelial cells) after 3 h of 
incubation. The MFI values of NPs inside the cells were quantified by flow cytometry in the 
presence or absence of each inhibitor. The average MFI of control cells without any inhibitor 
were set as 100% for normalization purpose and easy comparison. Normalized MFI values 
and standard errors of 3 to 6 independent experiments are shown.  
 
We used Alexa 448-labeled transferrin (2.5 µg/ml) as positive control for clathrin-
dependent endocytosis in the same manner for 100 nm polystyrene NPs in BMDMs, L929 
fibroblasts and 293T epithelial cells. As expected, the flow cytometry results show that 
chlorpromazine efficiently blocked the uptake of transferrin in all the three cell types, and 
cytochalasin D affected the uptake of the transferrin in BMDMs while other inhibitor even 
increased the uptake of transferrin (Fig. 23). The results validates the specificity of the 
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pharmacological inhibitors used to characterize multiple endoctotic pathways used by cells to 
uptake 100 nm polystyrene NPs.  
 
Fig. 23: Effects of different pharmacological inhibitors on the uptake of Alexa-448-labeled 
transferrin by different cell types (BMDMs, L929 fibroblasts or 293T epithelial cells) after 3 h 
of incubation. The MFI of cells treated with Alexa-448-labeled transferrin was set as 100% 
for clarity in each cell types. The result shows that chlorpromazine efficiently blocked the 
uptake of transferrin in all the three cell types, while other inhibitor had less effect or even 
increased the uptake of transferrin. The figure is the summary of three independent 
experiments with their respective SE.  
 
4.2.6 Effect of cell types on uptake mechanisms of polystyrene NPs 
The uptake mechanisms and pathways of NPs in different cells are not fully known. To 
investigate polystyrene NPs uptake potentials of BMDM, L929 mouse fibroblasts and 293T 
epithelial cells, each cell types were cultured and treated with 20 nm polystyrene NPs under 
equivalent cell culture conditions. Regardless of the differences in their biological properties, 
such as size and doubling times, all the cell types were treated with the same batch and doses 
of polystyrene NPs. After incubation for various time points, the uptake potential of 
polystyrene NPs by each cell types was quantified by flow cytometry. At 24 h of incubation, 
BMDM had taken up 100 or 5.5 fold more NPs than 293T epithelial cells or L929 fibroblasts, 
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respectively (Fig. 24). The experiments were also performed using fluorescence microscopy 
and similar results were observed for each cell type (data not shown), suggesting that the 
capacity to take up polystyrene NPs significantly differs among different cell types. In order 
to investigate the uptake kinetics, the uptake rate of NPs was measured at different time 
points. The results revealed that BMDM take up 33.8, 60.9 or 64 times higher numbers of 
NPs than 293T epithelial cells at 30 min, 2 h or 4 h incubation periods, respectively (Fig. 24). 
Compared to L929 fibroblasts, BMDM take up 1.9, 4.7 or 5 times more NPs at 30 min, 2 h 
and 4 h, respectively (Fig. 24). Even though the kinetics of the uptake varies between the cell 
types throughout the incubation period, the relative uptake differences were significant at all 
considered time points. Taken together, the results show that BMDMs take up 20 nm 
polystyrene NPs much higher than 293T epithelial cells and L929 fibroblasts at all considered 
time points.   
 
Fig. 24. A summary of relative uptake levels of 20 nm polystyrene NPs by BMDMs, L929 
fibroblasts or 293T epithelial cells. At all considered time points, the flow cytometric analyses 
showed clear differences in the relative uptake of NPs by the three cell types, being highest in 
macrophages and lowest in epithelial cells. The results are from three independent 
experiments and the values are presented as mean values ± SE. Normalization was done 
based on MFI from flow cytometry data.  
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4.2.7 Effect of size on the uptake mechanisms of NPs 
Various sizes of polystyrene NPs (200 nm, 500 nm, 1 μm and 2 μm) were used to study 
whether or not the size of NPs influences the uptake of NPs by BMDM, L929and 293T. 
Accordingly, cells were cultured and treated with the various sizes of NPs under the same cell 
culture conditions. The polystyrene NPs uptake potential of the three cell types at different 
time points were then quantified by flow cytometry. Normalization was done by setting the 
highest MFI of cells at 18 h as 100% for each NPs size to facilitate easy comparisons. The 
result showed that the MFI of polystyrene NPs increases according to their size in all the three 
cell types (Fig. 25). Nonetheless, flow cytometry result showed that the relative uptake 
efficiency of 293T and L929 are much higher for larger size NPs than smaller size as 
compared to BMDM (Fig. 25). Conversely, relative NPs uptake efficiency of BMDMs is 
higher for smaller sizes polystyrene NPs (≤500 nm) than larger sizes (>500 nm) as compared 
to the two other cell types. This finding suggests that the particle uptake by the three cell 
types might not follow commonly defined size limits. 
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Fig. 25. The summary of relative uptake kinetics of 0.2 µm, 0.5 µm, 1 µm and 2 µm 
polystyrene NPs by 293T epithelial cells, L929 fibroblasts and BMDMs at 1 h, 6h or 18 h 
incubation times. The data were quantified by flow cytometry and the results are the summary 
of three independent experiments.  
To further confirm the above observation, we conducted confocal microscopy study to 
see the relative polystyrene NPs uptake variation among the three cell types for the different 
sizes (0.2 μm, 1 μm and 2 μm). The confocal microscopy results clearly supported the notion 
that L929 and 293T cells show relatively better uptake tendency towards larger size particles 
(>500 nm)  than smaller sizes (≤500 nm) particles (Fig. 26A-C) as compared to BMDMs. 
This suggests that the smaller the particle size, the higher the relative uptake potential of 
BMDMs as compared to L929 and 293T cells. Regardless of the particles' sizes, longer 
incubation period were accompanied by higher uptake (MFI) in all the three cells types. In 
general, our data showed that the internalization extent and kinetics of NPs uptake varies 
based on particles' sizes and cell types.  
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Fig. 26: Representative confocal microscopy pictures showing the relative NPs uptake 
potential of 293T, L929 and BMDM cells. The figure shows uptake of 0.2 μm polystyrene NPs 
(A), 1 µm (B) and 2 µm (C) at 18 h time point. The result indicates that BMDM have relative 
better uptake tendency for smaller size particles than larger sizes; whereas L929 and 293T 
cells shows higher relative uptake for larger particle sizes than smaller sizes.  
 
4.2.8 Effect of Leishmania parasite infection on NPs uptake potential of macrophages 
L. major is an obligate intracellular protozoan parasite that causes infection in host 
macrophages and causes CL. Leishmania parasites have developed sophisticated strategies to 
manipulate the host macrophage responses to establish successful infection and ensure their 
own survival by triggering several pathways21,23. Particularly, it has been shown that 
macrophage endocytosis capacity is controlled by stimulatory and inhibitory processes144. For 
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instances, some intracellular pathogens overcome host innate immunity by impairing 
macrophages’ endocytosis mechanisms. Moreover, stimulatory molecules like CpG ODN 
have shown to enhance phagocytic activity of macrophages. We therefore hypothesized that 
infection of macrophages by L. major may negatively influence their NPs uptake potential 
and consequently affect the application of NPs in drug delivery systems against leishmaniasis. 
To test this hypothesis, BMDMs were generated, infected with L. major for 12 h and exposed 
to NPs for 24 h at 37°C. We then measured polystyrene NPs uptake potential of the infected 
BMDMs comparing to non-infected ones. The results from this study showed that the uptakes 
of NPs by BMDMs were decreased by at least 1.83 fold (from 38.8% to 21.2%) when infected 
with L. major (Fig. 27). The decreased uptake of NPs by L. major-infected macrophages may 
be associated with the pathogenesis of the infection that may suppress physiology of 
BMDMs. 
 
Fig. 27. Flow cytometric data showing the effect of L. major infection and cell activation 
status on cellular uptake of 20 nm NPs by BMDMs. The infection significantly reduced the 
uptake potential of BMDMs while activation by CpG ODN rescued it. The values are given as 
mean ± SE from three independent experiments. Normalization was done by setting MFI of 
activated BMDM as 100% for clarity. 
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To further investigate whether the reduction in NPs uptake potential of macrophages 
after L. major infection was time dependent or not, the uptake of 0.02 μm polystyrene NPs by 
BMDM were measured at various time points. At all considered time points, infection of 
BMDMs with L. major resulted in significant decreases of internalization potential of the 
cells, indicating that the parasite has an inhibitory effect on ability of macrophages to uptake 
NPs (Fig. 28). We explored whether activation of L. major-infected macrophages by CpG 
ODN may rescue the decrease in the uptake potential of infected macrophages. The BMDMs 
were either pre-incubated with CpG ODN (25 µg/ml) or solvent control for 30 min. Then, the 
BMDMs were incubated with the same doses and batch of NPs for 24 h. The flow cytometry 
data showed that the NP-uptake potential of L. major-infected BMDM could be restored by 
activating them with CpG ODN.  
  
Fig. 28: Flow cytometric data showing the effect of L. major infection on the potential of 
BMDMs to take up 20 nm NPs at different time points. This data shows that the 
accumulations of NPs inside non-infected BMDMs are higher than the corresponding infected 
BMDMs at all considered time points. The values are the summary of three independent 
experiments.  
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4.2.9 Intracellular trafficking of polystyrene NPs in BMDMs 
Endocytosis is an active cellular process by which living cells uptake nutrient, pathogen or 
other foreign materials. It also regulates various processes initiated at the cell surface to 
control all aspects of intercellular communications. These include signaling, immune 
surveillance, antigen-presentation, and cellular and organismal homeostasis in metazoans. As 
mentioned before (in Figs. 16, 20 and 21), we confirmed that polystyrene NPs are localized in 
endocytic vesicles (endosomes) immediately after their internalization. It was therefore 
important to analyze how the NPs are trafficking inside BMDMs after internalizations. The 
TEM result (above Fig. 20 and indicated by EE) shows that polystyrene NPs are localized in 
ultrastructural vesicles suggestive of early endosomes as early as 30 min. Moreover, it 
indicates that at 30 min time of incubation, only few NPs are transported to early endosomes. 
To further follow their trafficking inside BMDMs, lysotracker red was used. The dye has high 
selectivity for acidic pH and is commonly used as a marker for late endosomes/lysosomes41. 
We employed this dye to study whether internalized NPs are further transited through the 
endolysosomal pathway for attempt to degradation. Upon incubating BMDMs with NPs at 
37°C for 6 h, we observed robust co-localizations of NPs with lysostracker red, indicating 
their accumulation in late endosomes/lysosomes (Fig. 29). The data suggest that the final 
cellular localization of the NPs is in late endosomes/lysosomes. To further complement our 
observation, we incubated BMDMs with NPs for 6 h and performed TEM analysis. As can be 
seen in Fig. 29 (indicated as PL), the results suggest that the final cellular localization of the 
NPs is in structures suggestive of late endosomes/lysosomes. The NPs distribution inside 
BMDMs demonstrate that they are exclusively localized in the cytoplasm but not in nuclei, 
indicating the failure to transit across the nuclear envelope (Fig. 29, also shown earlier in Fig. 
20). 
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Fig. 29: Fluorescence microscopy and TEM images of BMDMs showing localizations of the 
NPs in late endosomes/lysosomes or phagolysosomes after 6 h of incubation. The fluorescent 
images indicate bright field (A), lysotracker red (B), 100 nm polystyrene NPs (C), overlay 
including channel for DNA counterstained with Hoechst (D) and their respective channel of 
NP-untreated control cells (E-H). The TEM image (I) shows localization of the NPs in late 
endosomes or phago(endo)lysosomes (PL). Scale bars = 5 µm (fluorescence images) or 0.6 
µm (TEM images). 
 
The co-localizations of lysotracker red with NPs also indicated that the particles 
resided in an acidic compartment (Fig. 29). Lysotracker red is considered to stain vesicles 
with an acid dissociation constant (pKa) of less than 5.2
12. The localization of NPs in acidic 
87 
 
organelles was further validated by lysosensor blue. According to the supplier’s information, 
this dye is almost non-fluorescent except when inside acidic compartments and used to 
measure pH of vesicles inside cells. The concentrations of dyes were kept as low as possible 
(5 μM) to reduce potential artifacts from overloading. The results showed that lysosensor blue 
co-localized with NPs after 6 h of incubation, confirming their localization in acidic pH (Fig. 
30). The pKa of lysosensor blue is ~5.1. Thus, we conclude that the NPs are localized in acidic 
intracellular vesicles during their trafficking in the endolysosomal cascade of BMDMs. Even 
though the mechanisms by which internalized particles can escape from endolysosome 
degradation are complex and not yet fully understood13, their pH level was found to be in the 
acidic range. As a result, the changes in pH may be considered as a trigger to activate 
controlled drug release inside the cytoplasm. 
  
 
Fig. 30. Confocal microscopy images of BMDMs showing the colocalizations of 100 nm 
polystyrene NPs with lysosensor blue staining intracellular acidic pH vesicles. The images 
indicate bright field (A), green fluorescent polystyrene NPs (B), lysosensor blue (C), overlay 
(D) and their respective  channels for control cells without lysosensor blue (E-H) at 6 h of 
incubation. The depicted pictures are representatives of two independent experiments. 
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4.3 Chapter three: Pathogen- and host-directed PHMB polyplex therapy for CL  
One of the recent efforts in addressing the challenges of traditional chemotherapy relies on 
exploring advanced drug delivery systems. As well as improved drug delivery systems, the 
host immunity also plays a decisive role for the successful treatments of CL. Thus, a 
combination therapy comprising of chemotherapy and immune modulators that able to 
activate host immune systems are of great importance. However, efficient delivery of nucleic 
acid-based immune modulators into host cells is a key challenge. Enclosing these immune 
modulators within a polymer could overcome the delivery challenges by improving passage 
across physiological or cell barriers. Moreover, such formulation could stabilize immune 
modulatory oligomers against degradation and aid wound repair. In this arsenal, in addition to 
its potent antileishmanial activity, we showed that PHMB binds the genomic DNA of L. 
major parasites forming PHMB/gDNA complex structures. Similarly, it has also been 
reported that PHMB can be used as siRNA transfection vehicle in hybrid form with iron 
oxide145. Moreover, CpG ODN have potential applications both as adjuvants and 
nonspecific immune modulators by triggering innate immunity against intracellular L. 
major146. Therefore, we hypothesized that PHMB could be used as carrier of CpG ODN for 
innovative drug delivery system-based host- and pathogen-directed combination therapy 
against CL. To test this hypothesis, a range of PHMB/CpG ODN polyplex formulations were 
prepared and characterized, and their bioactivities were evaluated and compared to the free 
components (PHMB or CpG ODN alone). 
Primarily, before evaluating the potential use of PHMB as a safe and effective carrier 
for CpG ODN, we first wanted to confirm whether PHMB binds CpG ODN to form stable 
nanostructures. Following addition of an excess PHMB to CpG ODN, we observed an instant 
reaction that converted colorless PHMB and CpG ODN in solution to a temporal milk color, 
suggesting interaction of PHMB and CpG ODN (Fig. 31a). To complements this observation, 
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we performed EMSA experiments. The results showed that PHMB forms polyplexes with 
CpG ODN at relative weight ratios of ≥ 0.25 as confirmed by retarded electrophoretic 
mobility of CpG ODN in 1% agarose gel (Fig. 31b). To clearly show the retention of CpG 
ODN in the wells, the same CpG ODN sequence but labeled with rhodamine red at 3’ termini 
(CpG-R) were purchased and the EMSA experiments were repeated. The results clearly 
confirmed that there is retarded electrophoretic mobility and retention of CpG ODN in the 
wells containing the polyplexes as compared to the free components (Fig. 31 e and f), 
confirming polyplex formation between PHMB and CpG ODN.  
 
Fig. 31. PHMB/CpG ODN interactions and their physicochemical characterization. 
Formation of PHMB/CpG ODN polyplexes were confirmed by EMSA in 1% agarose gel. The 
figure shows color change during PHMB/CpG ODN complexation (a), PHMB/CpG ODN 
polyplexes (b), PHMB/CpG-R polyplexes (c) and the same gel (c) with fluorescence 
measurement of CpG-R (d). With the exceptions of negative control and PHMB alone, all 
wells contained equal amounts (weight) of CpG ODN with various concentrations of PHMB. 
M represents 2-Log DNA ladder (0.1-10.0 kb, New England Biolabs) and N represents water 
for negative control. All indicated PHMB/CpG ODN ratios are in relative weight (w/w). 
®Indicates two month old PHMB/CpG ODN polyplexes.  
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To further characterize the particle size and zeta potential of the polyplexes formed 
between PHMB and CpG ODN, dynamic light scattering (DLS) and electrophoretic light 
scattering (ELS) were applied. Two formulations of the polyplexes were prepared by mixing 
PHMB to CpG ODN at relative weight ratio of 2:1 and 1:1, and stabilized by incubating them 
at room temperature for at least 20 min before measurement. The results showed that the 
polyplexes have highly reproducible sizes of 310.9 ± 30.5 nm and 285.3 ± 15.0 nm at relative 
weight ratio of 2:1 and 1:1, respectively (Fig. 32a and b), confirming that PHMB 
spontaneously bound CpG ODN and formed stable nanopolyplexes. The polydispersity index 
(PDI) values of the nanopolyplexes were shown to be less than 0.3, indicating a narrow size 
distribution or their monodispersity (Table 4).  
 
Fig. 32. A representative intensity distribution curves for particle size determination of 
PHMB/CpG ODN nanopolyplexes. The figures show intensity distribution curves of 
PHMB/CpG ODN measured by using DLS at a relative weight ratios of 2:1(a) and 1:1(b) in 
Millipore water. Each line color represents a single measurement. 
Ratio Particle size (nm) PDI 
2:1 310.9 ± 30.5 0.222 ± 0.04 
1:1 285.3 ± 15.0 0.260 ± 0.02 
 
Table 4. Physicochemical characterization of PHMB/CpG ODN nanopolyplexes. The table 
shows particle size determination by using DLS with their polydispersity index (PDI). The 
table shows result summary of three independent experiments for each ratio used with ±SE. 
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Moreover, to predict the long-term stability of the polyplexes between PHMB and 
CpG ODN, their zeta potential was measured by ELS. The summary of three independent 
experiments showed that the zeta potential was determined to be +33.3 ± 1.1 mV  (ratio 2:1) 
and -18.77 ± 0.4 mV(ratio 1:1), and dependant on the ratio of PHMB/CpG ODN (Fig. 33a and 
b).  
 
Fig. 33. Zeta potentail determination of PHMB/CpG ODN nanopolyplexes. The figures show 
representative examples of intensity mobility curves of PHMB/CpG ODN measured by ELS at 
a relative weight ratios of 2:1(a) and 1:1(b) in ISA water, showing positive and negative zeta 
potentials, respectively. Each line color represents a single measurement.  
 
To further evaluate stability of the nanopolyplexes between PHMB and CpG ODN, 
the polyplexes were prepared at 2:1 ratio and kept in a refrigerator (4°C) for two months 
before their physicochemical nature were again characterized by TEM and EMSA. The 
EMSA results confirmed an excellent stability of the complexes formed between PHMB and 
CpG ODN (Fig. 31b indicated by ®). Likewise, the TEM results showed that the polyplexes 
had an excellent stability. In addition, the TEM results suggest that the nanopolyplexes had a 
nanometer sizes and predominantly spherical morphology rather than cylindrical or rod forms 
(Fig. 34).  
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Fig. 34. Stability and morphology characterization of PHMB/CpG ODN polyplexes by TEM. 
Two representative TEM pictures showing the stability and spherical morphology of the 
nanopolyplexes. The polyplexes was prepared and kept at 4°C for two months before the TEM 
images were taken.  
 
To quantify the stability and specificity of the interaction between the PHMB and CpG 
ODN, we used ITC. ITC directly measures the heat generated or absorbed when molecules 
interact and provides a total picture of binding energetics. The ITC results show that PHMB 
can strongly bind CpG ODN with sequential binding. The detailed thermodynamic parameters 
include first binding affinity (K1= 2.04E6 ± 3.75E5 M-1), second binding affinity 
(K2=2.62E4 ± 8.0E3 M-1) and third binding affinity (K3=2.64E6 ± 1.2E6 M-1) to form 
polyplexes. The corresponding enthalpy changes (ΔH) for each binding affinity include –1.83 
± 0.43 kcal/mol, 16.47 ± 5.19 kcal/mol  and –16.71 ± 5.18 kcal/mol, respectively. ΔH 
represents  measure of the energy content of the bonds broken and created. The values are 
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indication of changes in hydrogen and van der Waals bonding. Negative value indicates 
enthalpy change favoring the binding. Moreover, the respective entropy changes (ΔS) for each 
binding affinity include -32.7 cal/mol/deg, 573 cal/mol/deg and -531 cal/mol/deg, 
respectively. ΔS is positive for entropically driven reactions. Taken together, the detailed 
thermodynamic parameters confirmed that there is strong interaction between PHMB and 
CpG ODN that can lead to formation of stable nanopolyplex (Fig. 35)  
 
Fig. 35. Physicochemical characterization of PHMB/CpG ODN nanopolyplexes by ITC. The 
figures show quantitative measurements of the strength of interaction between CpG ODN and 
PHMB at 2:1 relative weight ratio. Its corresponding thermodynamic parameters such as 
binding affinity (Ka), enthalpy changes (ΔH) and entropy changes (ΔS) were shown. The 
deviation is a result of the fitted curve obtained and the figure is a representative of three 
independent experiments.  
 
Furthermore, we investigated immune modulation property of the nanopolyplexes as 
compared to free CpG ODN or PHMB. We assessed whether the polyplex formation process 
during formulations positively or negatively affects the immunomodulatory properties of CpG 
ODN. To this end, the concentrations of several key cytokines were measured by ELISA from 
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supernatants of co-cultured BMDMs. The results showed that the cytokine productions by 
BMDMs for the nanopolyplxes and the free component (CpG ODN and PHMB) were 
increased by increasing their doses (Fig. 36). We were not able to obtain reliable measures for 
IL-4 and TNF-α in cells treated with the nanopolyplexes or the free components (data not 
shown). We also observed that PHMB itself stimulated the production of proinflammatory 
cytokines by activating macrophages (Fig. 36), further supporting its use as therapeutical 
agent against Leishmania infections. It has been consistently shown that the most commonly 
used antileishmanial drugs have immunomodulatory properties, and activate macrophages and 
dendritic cells to remove the parasites from the host cells. It has also been shown that PHMB 
does not induce significant production of TNF-α, IL-1α and the transcription factor nuclear 
factor kappa B (NF-κB) which can cause either apoptosis or stimulate the growth of 
transformed cells147. Moreover, based on the concentrations of IL-6, IL-12 and IL-10 
observed, the nanopolyplexes showed higher or comparable immune stimulation capacity as 
compared to free CpG ODN (Fig. 36).  
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Fig. 36. Effects of PHMB/CpG ODN polyplex formation process on cytokines production of 
BMDMs as compared to its free components.  The bar graphs show the level of IL-6 (a-c), IL-
10 (d-f)  and IL-12 (g-i)  production after PHMB, CpG ODN or PHMB/CpG ODN polyplex 
was added to BMDMs that were pre-activated with CpG ODN (1.5 μg/ml) for 30 min and 
further incubated for 48 h. Controls show cytokines level for non-activated BMDM. The 
concentrations shown for the polyplexes represent the dose of PHMB and the concentrations 
of CpG ODN are half of the indicated doses. The error bars show standard error of three 
independent experiments. 
Finally, we tested the potential to use PHMB with CpG ODN as host- and pathogen-
directed combination therapy against CL. This was done by measuring the nanopolyplexes’ 
cellular uptake efficiency, cytotoxicity and antiparasitic efficacy as compared to the free 
components. To know the uptake efficiency of the nanopolyplexes, flow cytometry analyses 
were performed. As previous depicted (in Figs. 9b and 11), our results showed that BMDMs 
take up the nanopolyplexes in time dependent manner. The uptake efficiency of CpG-R in the 
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polyplex form was enhanced by about 15 fold relative to the free form; while the uptake of 
PHMB-FITC as a polyplex was not enhanced, confirming that PHMB can deliver CpG ODN 
into macrophages. Because PHMB and CpG ODN incorporation into polyplex particles may 
quench the mean fluorescence of PHMB-FITC or CpG-R, the uptake measurements may 
underestimate the delivery potential. We next tested out if the polyplex formation process 
reduced the toxicity associated with PHMB or CpG ODN. PHMB has an excellent safety 
record topically and is widely used as preservative, an antimicrobial and antiseptic agent in 
clinics, homes and industry for many years worldwide. Nevertheless, as expected for a 
cationic polymer, cell toxicity was observed at high concentrations. Very recently, the safety 
of PHMB has been thoroughly reviewed by the Scientific Committee on Consumer Safety of 
the European Commission. Acute toxicity assessment was reported between 500 to 1000 
mg/kg body weight and a NOAEL of 54 mg/kg body weight from a dietary 12-months study 
in beagle dogs characterized by liver impairment, histopathological findings in the skin and 
liver among others148. In female rats, the systemic toxicity values have been reported to be 1-
2000 mg/kg148. We hypothesized that PHMB toxicity may be effectively counteracted when 
interacting with negatively charged CpG ODN. To test this hypothesis, different polyplex 
formulations of various PHMB to CpG ODN ratios were prepared and tested against BMDMs 
and 293T epithelial cells. Surprisingly, the results demonstrated that toxicity of PHMB/CpG 
ODN polyplexes showed a much higher IC50 value than PHMB alone against BMDM and 
293T epithelial cells (Table 2). Moreover, our results indicated that relative toxicity of 
PHMB/CpG ODN polyplexes increases with increasing the ratio of PHMB to CpG ODN 
(Table 2). This finding was further supported by zeta potential determination, and the results 
similarly showed that the higher the ratio of PHMB to CpG ODN, the more relative zeta 
potential of the polyplexes (Fig. 33a and b). The cationic nature of polymers (higher positive 
zeta potential) is typically associated with toxicity against host cells and decationizing is 
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expected to reduce toxicity149. Therefore, our results suggest that polyplex formation process 
considerably reduces the toxicity of PHMB. Taken together, we speculate that the toxicity 
properties of PHMB can be further improved by complexation/shielding of its positive 
charges with CpG ODN.   
We next designed an appropriate in vitro assay to determine the combined 
leishmanicidal efficacy of PHMB and CpG ODNA in polyplex and free forms. The IC50 
values against intracellular amastigotes were determined using BMDMs infected with the 
luciferase-transgenic L. major strain. As previously shown (in Table 1), the polyplexes 
enhanced antileishmanial activity against intracellular amastigotes while increasing selectivity 
by many fold. Whereas, the cytotoxicity of the polyplexes against L. major promastigotes 
showed relatively lower efficacy as compared to free PHMB. At the concentration used, CpG 
ODN alone did not show antileishmanial activity and host cell cytotoxicity activities. In drug 
development for leishmaniasis, amastigotes are the most important clinical stage of the 
parasites. Our results generally show that the nanopolyplex therapy against CL is not only 
improves the uptake of CpG ODN and cytoxicity of PHMB against host cells, it also 
significantly enhance antileishmanial effect of PHMB. Moreover, our findings suggest that 
the components of the polyplexes are bioactive after delivery into BMDMs and PHMB 
releases the CpG ODN from the nanopolyplexes inside BMDMs for overall synergistic effect 
against CL. In summary, our data suggest that PHMB is an effective nucleic acid entry-
promoting vehicle and best synergistic combination therapy with CpG ODN against CL by 
improving delivery to host cells as wells as targeting both the host immunity and Leishmania 
parasites.  
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5. DISCUSSION 
5.1 Discovery of PHMB as novel antileishmanial agent  
Leishmaniasis therapy remains very challenging and relies on only a few chemotherapeutic 
agents that lack appropriate efficacy, safety and affordability. This situation emphasizes the 
need for new, effective, affordable and noninvasive treatment options that overcome 
shortcomings in the present arsenal of CL treatments. In line with these need, we studied the 
use of PHMB as a potential antileshmanial compond. Our data demonstrate for the first time 
that PHMB is a potent antileishmanial candidate drug for topical applications against CL. Our 
results indicated that PHMB is more potent than the current standard antileishmanial drugs in 
vitro. From a clinical point of view, PHMB is one of the most promising substances available 
today for local treatment of wound150. Moreover, PHMB is a very inexpensive compound 
(about $10-50/kg) that has been widely used in clinics, homes and industry as a disinfectant 
and antiseptic for over 50 years worldwide117–119,151, suggesting its affordability in developing 
world where CL burden is commonly seen. The antileishmanial effects of PHMB here are 
twofold: it directly kills the parasites that cause the lesions as well as accelerates wound 
closure and improvement of the cosmetic outcome of CL by preventing secondary bacterial 
and/or fungal infections. Superinfection commonly causes delay in wound healing in 
ulcerative CL patients152. For topical applications, PHMB shows an excellent safety 
record116,153. There is no evidence for development of resistance against several bacteria116. It 
is also used for clinical treatment of Acanthamoeba keratitis patients120,121. A clinical trial 
results from  100 women diagnosed with human papilloma virus (HPV) infection also shows 
that the topic treatment with PHMB is a safe and promising approach, and it may avoid the 
use of invasive treatments154.  Thus, PHMB could be potentially used as effective topical drug 
against CL. 
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 Encouraged by the potency of PHMB against L. major promastigotes, we wanted to 
understand PHMB’s mode of action. Our results showed that PHMB permeabilized parasite 
membranes. Moreover, the results revealed that PHMB selectively condenses or damages 
parasite chromosomes through differential nuclear access as compared to the host cell 
chromosomes. Recently, it has been similarly shown that PHMB is taken up and kills diverse 
bacterial species through chromosomal condensation (Chindera et al., submitted). Consistent 
with our observation of the membrane disruption, PHMB’s antimicrobial effect has been 
associated with its specific interaction with acidic phospholipids in microbial membranes, 
resulting in possibly forming pores and their disruption, while the neutral phospholipids in 
human cell membranes are only marginally affected118,129. Moreover, PHMB’s bactericidal 
action was also associated with its strong and cooperative interactions with nucleic acids in 
vitro130. Nonetheless, lack of any resistance development  to the polymer despite many years 
of use in wide varieties of fields may also indicate its multiple and complex mechanisms of 
action118. Thus, our findings help to explain how PHMB provides a potent broad-spectrum 
antimicrobial biocide against diverse microbes.  
In our attempts to understand how PHMB selectively act on parasites’ chromosomes 
without affecting the DNA of the mammalian host cells, we investigated its uptake 
mechanism and intracellular trafficking in BMDM. We showed that PHMB or its polyplexes 
are predominantly taken up by macrophages via dynamin-dependent endocytosis in a time-
dependent manner. It then exclusively localized in the cytoplasm without entering the nuclei 
of mammalian cells, indicating failure to transit across the nuclear envelope. However, there 
is no apparent exclusion of PHMB from the nuclei of the parasites, indicating its 
host/pathogen selectivity. Taken together, we described for the first time how mammalian 
cells internalize PHMB for its broad spectrum intracellular antimicrobial activity and 
selectivity against the host cells. 
100 
 
In concussion, given its very reasonable cost and long history of safe topical use, PHMB 
may be repositioned as drug against CL following appropriate in vivo experiments and clinical 
trials.   
5.2 Understanding the interactions between NPs and host cells 
 
The use of nanotechnology in every field of science is rapidly spreading. Particularly in 
medicine, the applications of nanotechnology improve diagnosis and therapy of diseases 
through effective delivery of drugs, biopharmaceutical molecules and imaging agents to target 
cells or tissues at disease sites41,42,155. For such applications, initial recognition of NPs by the 
immune system is essentially determinant for the fate and distribution of materials inside the 
body100. Thus, a better understanding of how cells take up NPs may lead to the development 
of enhanced antigen-, drug- or other molecules- delivery tools. In this scenario, we tried to 
elucidate the internalization mechanisms of various size commercially available polystyrene 
NPs by different mammalian host cells and to explore the factors affecting their uptake. Our 
results show that as many as 95% of NPs are generally taken up via an energy-dependent 
process at all considered time points in BMDMs. Although lowering the culture temperature 
affects both an active and a passive mode of entry (diffusion), it has been demonstrated 
previously that diffusion is not the rate-limiting step for NPs uptake into cells. Thus, blocking 
uptake pathways by drugs leads to inhibition of active transport, rather than a reduced NPs 
diffusion156. This finding is in accordance with studies from other group which showed that 
cellular uptake of NPs is predominantly mediated by endocytosis88,98.  In contrast, it has also 
been reported that NPs are taken up via non-endocytic pathways. For instance, Mu et al. 
suggested a passive mode of entry after observing NPs inside cells at 4°C157. We also 
observed about 5% uptake in cells kept at 4°C at different time points. However, the status of 
the cells before exposure to NPs may have some influence for such uptake at 4°C. Because 
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the cells might have limited energy from pre-incubation at 37°C that may be exhaustively 
used for such active cellular processes during the early period of incubation at 4°C. Indeed, 
we observed a decrease in uptake at 4°C when we increased the pre-incubation on ice from 10 
min to 30 min before exposing the cells to the NPs. Altogether; we conclude that NP uptake is 
predominantly achieved by endocytic processes in an energy- and time-dependent manner.   
The cellular uptake mechanism of NPs is influenced by multiple factors158, among 
which the physicochemical properties of NPs are considered to be the main determinants of  
the import and subsequent intracellular trafficking of the NPs. Particle size and charge is 
likely the primary factor that governs endocytic uptake of particles. Our in vitro cellular 
uptake experimental results indicated that the relative uptake efficiency of 293T and L929 
increases with sizes of NPs as compared to the BMDM. On the contrary, relative NPs uptake 
efficiency of BMDMs is higher for smaller sizes polystyrene NPs as compared to 293T and 
L929 cell types. Many groups have showed that cellular uptake of NPs is size dependent and 
is significantly faster  for smaller particles than larger particles in antigen-presenting 
cells159,160. However, the non-professional phagocytes like epithelial cells  uptake smaller NPs 
more efficiently than large particle size161,162. Interestingly, in line with our finding, it has also 
been shown that cells non-specialized for phagocytosis were able to internalize as large as  2 
µm NPs96. Our result suggests that the particle uptake might not follow commonly defined 
size limits for uptake processes by different cells. The difference of our findings from the 
others might be resulted from the approaches we followed. Many size dependent uptake 
studies simply compare the uptake efficiency of different size NPs by measuring the 
percentage of uptake by particular cell type without first considering the differences in 
fluorescence intensity among the different NP sizes themselves. However, we compared the 
relative uptake potential of the three cell types for particular particle size at a time so as to 
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insure that the variations in MFI among the cells types are resulted from the difference in 
uptake potentials rather than fluorescence intensity deviations among the different NP sizes.  
 Moreover, it has been shown that increasing surface charges of NPs (positive or 
negative) have been shown to increase particle uptake in comparison with uncharged ones163. 
It has been also suggested that NPs with positive surface charge are taken up more efficiently 
than negatively charged NPs164. Another important factor is the degree of aggregation and 
protein corona. The arrival of NPs into the dynamic extracellular environment may change the 
protein corona, size or aggregation. These change may consequently affects many aspects of 
NP-cell interactions including mode of particle uptake because the biological identity of a 
NPs depends on the composition of the surrounding biological medium165. It has also been 
shown that increasing NPs incubation time may induce NPs aggregation and changes in  
protein corona composition that subsequently determine cellular uptake mechanisms165. We 
further explored cell types as a factor influencing the NPs entry pathways. We showed that 
the potential to take up NPs is highly different for BMDM, 293T epithelial cells and L929 
fibroblasts, being highest for macrophages followed by fibroblasts for 20 nm NPs, indicating 
variability of uptake kinetics for the same material in different cell types. This finding is in 
line with a previous report by dos Santos et al. which showed that the uptake of different sizes 
of NPs varies in different cell lines, being highest in macrophages and lowest in the HeLa 
cells96. The differences in the uptake rates of BMDMs (professional phagocytes) and non-
professional phagocytes (293T epithelial cells and L929 fibroblasts) may be due to 
differences in the number or type of endocytic pathways involved to internalize the NPs. In 
contrast to 293T epithelial cells and L929 fibroblasts, BMDMs may use multiple uptake 
routes simultaneously for relatively smaller particle sizes. In summary our data showed that 
cellular uptake of NPs is influenced by several factors associated with either physiochemical 
properties of the NPs or its surrounding environments.   
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Furthermore, we looked whether NPs import is influenced by microbial infection. We 
demonstrated that infection of BMDMs with L. major significantly decreased the cellular 
uptake of NPs. The effect of L. major infection on macrophages has been investigated by 
many researchers and demonstrated that the parasite can subvert macrophage responses by 
regulating different genes including those responsible for endocytosis and cell adhesion21–23. 
However, the mechanism(s) by which the parasites subvert macrophages is (are) still remain 
poorly understood. In our group, it was previously shown that the parasite induces down 
regulation or upregulation of cytokine and chemokine expression profiles as a mechanism of 
subversion166. It represses the production of inflammatory cytokines (TNF-α, IL-6, IL-12) 
which are  very essential for the survival and multiplication of the parasites inside 
macrophages166,167. Moreover, it has been shown that some intracellular pathogens have 
inhibitory mechanisms to suppress macrophage physiological functions. Recently,  it has been 
shown that macrophages infection with HIV-1 virus would result in impairment of its 
phagocytic function168. Similar to our findings, Basu et al. have showed  a 2-fold decrease in 
uptake rate in Leishmanai infected macrophages through a decrease in endocytosis receptors 
after infection; whereas recovery of receptor activity and uptake potential were observed after 
elimination of parasites from macrophages169. Thus, these findings suggest that the decreased 
uptake of NPs by L. major-infected macrophages may be associated with a kind of "silencing 
effect" of the intracellular parasite on BMDMs. We also showed that the activation status of 
macrophages has a significant effect on their uptake potential. The uptake of NPs was 
significantly enhanced in CpG ODN-activated macrophages as compared to non-activated 
control cells. It shows that CpG ODN could rescue the decrease in NPs uptake of BMDMs 
due to L. major infection. These results are also in agreement with the previous findings. 
Gupta et al. showed that CpG-ODN has a promising efficacy against L. major in vivo rodent 
experiments through activation of host immune responses and consequently,  could revert the 
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effect of the parasite on macrophages114. Similarly,  it has also been shown that endocytic 
activity of macrophages is enhanced in response to CpG ODN170,171. As a result, the observed 
effect of CpG-ODN could be either through activation of the macrophages to increase the 
uptake of the NPs or to kill the intercellular parasite in order to decrease the parasite effect on 
BMDMs.  
The distinct endocytic pathways are highly regulated to control all aspects of 
intercellular communications and have been associated with many factors134,172. However, it 
has not yet been fully known whether a single cell or cell type uses several uptake pathways 
simultaneously for a given NPs. As can be clearly seen in our TEM and inhibitor studies 
results, a cell may utilize multiple endocytic pathways simultaneously to internalize a given 
type of particles. Interestingly, all these distinct uptake routes were observed in the same 
BMDM after treating with 100 nm NPs sizes for 30 min, confirming the use of several routes 
by cells to uptake a given NPs. Our TEM analysis revealed that an uptake pathway that 
requires a larger size of NPs (phagocytosis or macropinocytosis) may be triggered by a 
number of smaller particles or their aggregates, approaching a specific area of the plasma 
membrane giving the uptake signal. This signal most probably controls the type of protein 
recruitment in the area of initiation and the type of endocytic pathway that should be in place 
for the uptake of NPs via protein-lipid and protein-protein interactions92,135,173,174. The 
sonication of NPs to generate single particles is very important in such type of studies since 
the uptake mechanisms for a specific NPs and their aggregate may differ. Even though it is 
believed that there are several endocytic pathways for uptake of various NPs by a given cell, 
to our knowledge this is the first evidence based on ultrastructural analysis documenting 
multiple uptake routes simultaneously to internalize a given type of NPs. Blocking distinct 
endocytosis pathways by inhibitors corroborated this conclusion. None of the treatments with 
different inhibitors fully inhibited NPs uptake but some inhibited more strongly in one cell 
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type than others. For instance, wortmannin, cytochalasin D and chlorpromazine inhibited the 
NP uptake in BMDMs more strongly than in L929 and 293T cells, suggesting that some 
pathway might be more sensitive to the inhibitors in one cell type than in the others. In line 
with our results, a recent study showed that polyelectrolyte multilayer capsules of a few 
micrometer size are taken up by cells via multiple pathways such as lipid rafts, 
macropinocytosis or phagocytosis175. The authors used larger particle sizes and, consequently, 
identified larger size uptake pathways such as macropinocytosis and phagocytosis. However, 
unlike in our study, they could not identify the smaller size uptake pathways like clathrin, 
caveolin or clathrin- and caveolin-independent uptake pathways. This difference can be 
explained by the fact that the sizes of the NPs used in this particular experiment for 
identification of different routes were 0.02 μm or 0.1 μm, while the sizes of the multilayer 
capsules were in the micrometer range. 
Our TEM and co-localization studies further showed that the NPs localize in 
membrane-bound endosomal vesicles soon after their internalizations and are subsequently 
trafficked to late endosomes/lysosomes. Different from this finding, Johnston et al. reported 
that polystyrene NPs are not contained in early endosomes or lysosomes in hepatocytes176. On 
the other hand, many investigators described that the NPs enter a lysosome-associated 
membrane protein 1 (LAMP-1)-positive lysosomal compartment in macrophages138,177. These 
differences may be explained by the use of different cell types or methodology approaches. 
Generally, it has been shown that cells internalize NPs by different types of endocytosis, 
resulting in their accumulation in different endocytic vesicles or tubules after engulfing. NPs 
are then transported to early endosomes and either transported back to the membrane surface 
by exocytosis (not very common in NPs), or further transported through late endosomes or 
multivesicular bodies to lysosomes for attempting to degrade88,178,179.  
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In conclusion, the results presented in this study provide a detailed analysis of multiple 
cellular uptake mechanisms of fluorescent polystyrene NPs and factors affecting their uptake 
mainly in BMDMs. The data showed that NPs are rapidly internalized and accumulated in 
endosomal compartments, indicating their ability to entry into different cell types. Once the 
NPs are internalized by host cells, they localize in endosomes and then traverse to acidic pH 
vesicles through the endolysosomal pathways. The NPs uptake is an energy-dependent 
process that highly depends on NPs’ sizes, cell types and time. Cells may use several distinct 
types of endocytosis pathways simultaneously for the uptake of a given type of particles. Even 
though particles of larger size (a few micrometers) are usually taken up by phagocytosis or 
micropinocytosis, our findings suggest that smaller NPs are internalized by multiple 
endocytosis routes including macropinocytosis, phagocytosis, clathrin-mediated endocytosis, 
caveolae-mediated endocytosis, and clathrin- and caveolae-independent pathways. Our 
findings highlight the complexity of cell-nanoparticle interactions beyond the previous 
assumptions, and the need of case-by-case studies to achieve the goal of manipulating NPs to 
control their entry pathways. Furthermore, physicochemical properties of the NPs have been 
considered as the main factors determining the cellular uptake and intracellular pathways of 
NPs. However, our study showed that the type of infection or disease pathogenesis and/or the 
cell activation status also significantly affects the potential of BMDMs to take up NPs. Since 
this may consequently determine the application of NPs in biomedical delivery systems, our 
findings emphasize the need to understand the diseases’ pathogenesis in order to establish 
effective and rationally designed drug delivery systems. These observations may enhance our 
understanding of the application of nanotechnology in biomedical sciences.  
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5.3 PHMB nanopolyplex therapy for CL  
The prevalence of leishmaniasis is estimated to be 12 million in 98 countries across the globe, 
of which two-third of the cases are CL presentations180. CL is characterized by skin ulcers that 
carry significant scarring and causes a social stigmatization. Regardless of the enormous 
efforts made so far, there is still no new commercial drug available, and the existing therapies 
against CL are far from being satisfactory. Single therapy approach has often resulted in 
suboptimum clinical efficacies with high risk to benefit ratio, indicating the complex nature of 
the disease. It has been suggested that multidisciplinary and parallel synergistic approaches 
are important strategy to sustain the modern practice of medicine181. Thus, curative CL 
therapy may need combinations of multiple strategies including chemotherapy, modulation of 
host immunity and advanced drug delivery systems. Particularly, combination therapies that 
simultaneously kill the pathogen and manipulate the host immune system for overall 
synergistic therapeutic effect would be an ideal therapy for CL patients. Therefore, 
technologies that enhance delivery and antileishmanial immune responses may improve the 
overall outcomes of CL treatments. On the other hand, as well as eradication of the 
intracellular parasites causing the lesions, effective treatment of CL includes wound 
management caused by the parasites. In these contexts, we investigated PHMB and CpG 
ODN polyplexes as combined therapy as well as advanced drug delivery systems against CL. 
We clearly showed that PHMB and CpG ODN form self-assembled nanopolyplexes that are 
readily taken up by macrophages, increasing the uptake efficiency of CpG ODN and 
increasing the potency and selectivity of PHMB against L. major. This could probably 
provide potent and synergistic combination therapy for Leishmania infections, without the 
toxicities associated with currently used drugs. Moreover, our results suggest that PHMB 
could be potentially used as effective non-viral nucleic acid delivery vehicle. In principle, 
such nanopolyplex formulations are used for sustained long-term release rather than an 
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immediate quick release, which would also be beneficial for topical dermatological 
applications and controlling toxicity.  
Recently, host-directed treatment strategies were suggested to improve treatment 
efficacy and outcome, represent feasible alternatives to conventional approaches182.  It has 
been suggested that modulation of the immune microenvironment in CL is a potential 
therapeutic and prophylactic target183. Indeed, immune deviation towards Th1 responses by 
immune modulating agents  show promising efficacy against leishmanaisis114,184,185. In this 
scenario, CpG ODN is a potent immune modulator that activates macrophages and dendritic 
cells to kill intracellular L. major parasites146. CpG ODN can also accelerate wound 
repair186,187. Moreover, polyplex formulation of CpG ODNs could also stabilize oligomers 
against degradation, increase killing within macrophages by enhancing uptake and aid wound 
repair. In line with the effect of CpG ODN on the host, it has recently been shown that the 
traditional antileishmanial drugs critically modifies the maturation, activation and 
development of phagocytes through a mechanism dependent on TLR9 and MyD8829. 
Moreover,  it has been known that lipophosphoglycan (LPG), a virulence factor expressed by 
Leishmania parasites, activate TLR-2 to reduce antileishmanial immune responses of 
macrophages via cytokine-mediated decrease of TLR-9 expression188. Conversely,  it has also 
been shown that activation of TLR-9 by CpG ODN have potential applications both as 
adjuvants and nonspecific immune modulators by triggering immunity against intracellular L. 
major146. Similarly, paromomycin is being used in combination with methylbenzethonium 
chloride (Leshcutan adjuvant) to increase the amount of drug that is delivered to the skin for 
local treatment of CL107,189.  
On the other hand, recent studies show that stimulating the innate immune system by 
CpG ODN may accelerates wound repair and represents a novel, inexpensive, safe and 
effective means of improving wound repair186,187. The CpG ODN induced the production of 
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cytokines, chemokines, and growth factors that act on inflammatory and epithelial cells at the 
wound site to enhance wound healing186,190. Moreover, it has been shown that CpG ODN and 
chemotherapeutic delivery system not only lowers the effective drug dose and toxicity but 
also synergizes with the upregulation of tumor necrosis factor alpha (TNF-α), interleukin-12 
(IL-12), and inducible nitric oxide synthase and with the down regulation of transforming 
growth factor β (TGF-β), IL-10, and IL-4  in leishmanai infection models 72,191,192. Evehtough 
CpG ODN has an important role in both producing antileishmanial immune responses and 
wound management, efficient delivery of nucleic acid-based immune modulators like CpG 
ODN is a key challenge. This has been overcome by enclosing CpG ODN within PHMB and 
could overcome the delivery challenges by improving passage across physiological or cell 
barriers. Such delivery strategies may also favor the creation of a drug reservoir in the dermis 
by sustained release systems or enhance skin penetration of drug. Thus, a technology that 
combines PHMB and CpG ODN could kill parasites directly through parasite membrane and 
chromosome disruption, and indirectly through modulation of host immunity. 
Moreover, the wound healing and antileishmanial effects of PHMB may be further 
facilitated by immunomodulatory property of CpG ODN. The discovery of PHMB-nucleic 
acid interactions and formation of nanopolyplexes for efficient delivery into macrophages 
may have vast applications beyond the initial objectives of this study. Our study indicated that 
the efficacy and the selectivity of drugs for CL can be drastically improved through an 
advanced drug delivery system and a combination therapy. Taken together, our finding has 
great translational implications for the treatment of CL and nucleic acid-based 
therapy/vaccine.  
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6. SUMMARY AND OUTLOOK  
Several infectious diseases caused by intracellular pathogens including leishmaniasis cause 
enormous suffering in many countries. The global burden of leishmaniasis is exacerbated by 
the lack of licensed vaccines. Current treatments of CL are poorly justified and have sub-
optimal effectiveness. Traditional antileishmanial systemic agents such as antimonials, 
pentamidine and amphotericin are limited by toxic side effects, parenteral route of 
administration and emerging drug resistance34. Topical or local treatment has been 
recommended by the WHO as a first line treatment approach for CL patients; however, they 
have not yet provided a strong consistent result either. WHO recommended a simple wound 
management as a first line treatment approach for non-complicated CL cases. Overall, there is 
a lack of evidence for potential benefit of the current CL treatments. New efficacious, 
affordable and noninvasive therapeutic drugs are desperately needed. Among several 
drug discovery research strategies, repurposing or repositioning existing drugs from other 
diseases accounts for many currently used antiparasitic drugs, and thus, have historically 
played a great role in antiparastic drug discovery193. It has been a rationale for development of 
amphotericin B, miltefosine and paromomycin against leishmaniasis. This particular approach 
has a number of advantages including reduction in development times, costs, and overall 
risks. In this study, we discovered PHMB as a novel, affordable and potent antileishmanial 
agent that could potentially be used for topical treatments of CL patients. PHMB has long 
history of safe topical usage for several purposes including for dermatological and wound 
managements.  
For effective targeting of intracellular pathogens including Leishmania parasites, an 
efficient uptake of drugs by phagocytes is an important prerequisite40. For intracellular 
localization of drugs in macrophage-rich organs such as liver, spleen and bone marrow, NPs 
holds great promise. When NPs are introduced into a medium, opsonin proteins are attached 
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to the surface of NPs, and they are then tend to be recognized by phagocytes as 'foreign'.  
Consequently, they are preferentially taken up by the intended target cells (phagocytes) much 
more effectively than their free drug counterparts194. Among various NPs platforms, cationic 
polymer NPs  are known to  improve cellular uptake, biodegradability and biocompatibility of 
drugs195. Moreover, they can also be used to manipulate or deliver immunologically active 
components to the target sites more effectively. Thus, understanding of biological pathways 
for internalization of the NPs can facilitate precise intracellular targeting with enhanced 
therapeutic outcomes. By using standardized commercial polystyrene NPs as model, we 
studied the interactions of NPs with biological systems. We showed that NPs are internalized 
by several endocytic routes. Moreover, there are also various physicochemical and biological 
factors that determine NPs-cell interactions.  
Finally, we attempted to develop innovative NPs based host- and pathogen-directed 
therapy for successful treatment of CL. The treatment approach focused on a combination 
therapy that can simultaneously kill the pathogen selectively and manipulate the host immune 
system in favor of elimination of the parasite for overall synergistic effect against CL. In this 
scenario, we investigated the overall synergistic effect of a combined therapy comprising 
PHMB and CpG ODN against CL. Our results clearly showed that PHMB and CpG ODN 
form self-assembled nanostructures that act through the host immune modulation and directly 
killing the intracellular parasites. This suggests that PHMB can be potentially used as non-
viral nucleic acid carrier and a combination therapy with CpG ODN for effective host- and 
pathogen-directed therapy against CL. Regardless of its excellent safety record, as expected 
for a cationic polymer, PHMB shows cell toxicity at high concentrations. However, our 
results suggested that PHMB toxicity could be effectively counteracted when interacting with 
negatively charged CpG ODN as a result of effective charge shielding upon complexation 
without minimizing its antileishmanial effect. This nanopolyplexes potentially provide 
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additional benefits through wound healing, immune modulation and cellular delivery. It is a 
novel idea that constitutes rationale-based combination therapy and an innovative 
nanotechnology strategy. Unlike other combination therapies, in this technology, PHMB 
condense nucleic acids into smaller particles forming nanopolyplexes for enhanced delivery, 
while allowing it to dissociate once inside the cell. Conclusively, our proof-of concept study 
showed that PHMB with or without the nucleic acid immunomodulator could be effectively 
used to challenge CL. Therefore, our findings have a great implication to combat human 
diseases by opening a new methodology for nucleic acid-based therapy and/or vaccine.  
For several reasons such as low-cost, high-throughput, and accuracy in efficacious 
determination, in vitro experimental systems are ideal196. However, one of the main 
challenges in drug development research is many candidate drugs that are initially promising 
in cell culture may not retain the same efficacy in laboratory animals or in clinical trials. The 
additional barriers present in the physiological environment may prevent successful 
translation of in vitro study into animal study. Furthermore, the treatment strategies of CL and 
its outcomes differ based on the type of parasites causing the diseases197. Thus, the idea of 
using PHMB with or without CpG ODN for topical application against CL has to be further 
studied and evaluated in in vivo animal model(s). Moreover, the discovery should be 
evaluated against a range of Leishmania genus, species and strains. In summary, further 
appropriate in vitro and in vivo studies, and clinical trials are warranted to take the currently 
identified novel candidate drug to clinics. 
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8.  ABSTRACT  
Despite huge suffering caused by cutaneous leishmaniasis (CL), there is no effective and 
affordable treatment strategy against CL and no licensed vaccines. The current treatments 
show limited efficacy and high toxicity. Improved therapies through discovery of novel drugs 
and/or an alternative treatment approaches are/is urgently needed. We aimed at identifying a 
novel antileishmanial agent and developing an innovative nanoparticle (NP) based platform 
for safe and effective treatments against CL. We discovered that polyhexanide (PHMB), a 
widely used antimicrobial polymer and wound antisepsis, shows an inherent antileishmanial 
activity at submicromolar concentrations. PHMB appears to kill L. major parasites via a dual 
mechanism involving disruption of membrane integrity and selective chromosome 
condensation. However, host chromosomes binding appear to be limited by exclusion from 
mammalian cell nuclei. Moreover, we attempted to establish effective drug delivery systems 
that overcome the various shortcomings in the present treatment of CL. In this scenario, we 
initially studied the cellular interactions of NPs and their uptake mechanisms into mammalian 
cells before applying them in drug delivery system. We obtained clear evidence for the 
involvement of multiple endocytic routes to internalize NPs. Physicochemical properties of 
NPs, cell type, temperature and pathogenesis of the target diseases were shown to be 
determinant factors. Thereafter, a mechanism based host- and pathogen-directed combination 
therapy comprising PHMB and CpG ODN immunomodulator was established for overall 
synergistic effect against CL. It simultaneously targets the pathogen and the host immunity 
with effective delivery system. The results show that PHMB binds to CpG ODN and form 
stable nanopolyplexes for efficient cell entry and therapy. The nanopolyplexes displayed 
enhanced cellular uptake and antileishmanial potency while drastically reducing the toxicity 
against mammalian cells. In conclusion, our findings clearly indicate that PHMB can be used 
as effective candidate drug against CL and as non-viral delivery of immunomodulatory 
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nucleic acids. Moreover, our proof-of concept study showed nanomedicine approaches are 
effective strategy to challenge CL and other human diseases.  
 
Zusammenfassung 
Obgleich enorme Leiden mit der kutanen Leishmaniose einhergehen stehen bis dato keine 
wirkungsvollen und erschwinglichen Therapien oder zugelassene Impfstoffe zur Verfügung. 
Die derzeitigen Behandlungsmethoden sind kaum effektiv und zeichnen sich vor allem durch 
ihre enormen Nebenwirkungen aus. Aus diesem Grund ist die Erforschung neuartiger 
Wirkstoffe und Therapieansätze gegen kutane Leishmaniose zwingend notwendig. Die 
vorliegende Arbeit beschreibt die Entdeckung eines neuen antileishmanialen Wirkstoffes und 
die Etablierung eines innovativen und auf Nanopartikeln basierenden Verfahrens zur sicheren 
und effizienten Behandlung der kutanen Leishmaniose. Das Polyhexanid, welches bereits 
Verwendung als antimikrobielles Polymer und als Wundantiseptikum findet, weist bereits in 
submikromolaren Konzentrationen eine immanente antileishmaniale Wirkung auf. Den 
Beobachtungen zu Folge beeinflusst das Polyhexanid die Integrität der parasitären 
Zellmembran und führt zur selektiven Chromosomenkondensation des Parasiten Leishmania 
major. Eine potentielle Chromosomenmodifikation in der Säugetierzelle wird durch den 
Ausschluss des Polyhexanides aus dem Zellkern verhindert. Um die zahlreichen Mängel der 
aktuellen Behandlungsmethoden gegen kutane Leishmaniose zu überwinden, wurde zudem 
ein effizientes System der Wirkstoffabgabe etabliert. Diesbezüglich wurden zunächst die 
zellulären Wechselwirkungen der Nanopartikel und deren Aufnahme in die Säugtierzelle 
untersucht ehe diese als Vehikel für den Wirkstoff verwendet wurden. Es konnte gezeigt 
werden, dass die Nanopartikel über mehrere endozytische Wege internalisiert werden. 
Physikochemische Eigenschaften der Nanopartikel, der Zelltyp, die Temperatur und 
erregerspezifische Pathogenese gehören zu den beeinflussenden Faktoren. Daraufhin wurde 
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eine Kombinationstherapie bestehend aus Polyhexaniden und dem unmethylierten 
Immunmodulator Zystein-Phosphat-Guanin Oligodeoxynukleotid mit synergistischen 
antileishmanialen Auswirkungen, etabliert. Dies gestattet eine gegen den Erreger 
zielgerichtete Behandlung und die zeitgleiche Stimulierung der Wirtsimmunität. Die Bildung 
eines stabilen Nanopolyplexes bestehend aus dem Polyhexanid und dem oben genannten 
Immunmodulator befähigen die effiziente Aufnahme in die Zelle und somit die Behandlung. 
Der Nanopolyplex ermöglicht eine verbesserte Aufnahme in die Zelle und antileishmaniale 
Wirksamkeit wohingegen die Toxizität gegenüber Säugetierzellen drastisch reduziert ist. 
Zusammenfassend lässt sich feststellen, dass Polyhexanide als effizienter Wirkstoffkandidat 
gegen kutane Leishmaniose und als nicht-viraler Träger von immunmodulatorischen 
Nukleinsäuren zu betrachten sind. Zugleich wurde gezeigt, dass die Nanomedizin einen 
wertvollen Beitrag zur Bekämpfung der kutanen Leishmaniose und sicherlich auch anderer 
Krankheitserregern leisten kann.  
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10. ABBREVIATIONS  
 
APC   Antigen-presenting cell 
BMDC Bone marrow-derived dendritic cell 
BMDM Bone marrow-derived macrophages 
CD Cluster of differentiation 
CL Cutaneous leishmaniasis 
CpG ODN              Cytosine-phosphate-guanosine oligodeoxynucleotide  
CpG-R R hodamine -red CpG ODN 
DCL    Diffuse cutaneous leishmaniasis 
DMEM Dulbecco's modified eagle medium 
DNA     Deoxyribonucleic acid 
ELS Electrophoretic light scattering  
ELISA Enzyme-linked immunosorbent assay 
EMSA Electrophoretic mobility shift assay 
FACS Fluorescence activated cell sorting 
FITC 
 
Fluorescein isothiocyanate 
FM4-64FX Fei Mao fixative form 
gDNA Genomic DNA 
HPV Human papilloma virus  
IFN-γ Interferon gamma  
IL Interleukin 
ITC Isothermal titration calorimetry  
L. major Leishmania major 
LPG Lipophosphoglycan 
M-CSF Macrophage-colony stimulating factor  
MDR Multidrug resistance  
MFI Mean fluorescence intensity  
MHC Major histocompatibility complex 
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NF-κB the transcription factor nuclear factor kappa B  
NP Nanoparticle 
PBS Phosphate-buffered saline  
 
PFA Paraformaldehyde 
 
PHMB Polyhexamethylene biguanide 
PRRs Pattern-recognition receptors  
PI3K  Phosphatidylinositol 3-kinase  
RPMI Roswell park memorial institute  
RNA Ribose nucleic acid 
TEM Transmission electron microscopy 
TGFβ Transforming growth factor β 
Th T helper 
TLR Toll-like receptor 
TNF-α Tumor necrosis factor alpha  
VL Visceral leishmaniasis 
WHO World health organization  
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06/12 – 08/12  Research stay at Dr. Conor Caffrey, Department of Pathology, School of 
Medicine, University of California, San Francisco, USA.   
03/12  Intercultural training organized by Graduate School of Life Science, 
University of  Würzburg, Würzburg, Germany. 
03/12 The 6th short course for Young Parasitologist (one week), Heidelberg 
organized by Germany Society for parasitology and University of 
Heidelberg , Heidelberg, Germany. 
02/12 Poster Design and Presentation organized by Grduate School of Life 
Science, University of  Würzburg, Würzburg, Germany. 
09/11 Laboratory animal sciences course CAT. B FELASA for one week in 
Berlin, Germany. 
08/11 Information Technologies in Health Care and Life Sciences Graduate 
School of Life Science, University of  Würzburg, Germany. 
08/10 Tuberculosis Epidemiology and Microbiology, workshop for one week, 
organized by European and Developing countries clinical Trials 
Initiatives held at National Institute for Medical Research though 
(EDCTP), Dar es Salaam, Tanzania. 
02/10 M. tuberculosis drug resistance,   DNA Microarray, Sequencing, and 
other molecular and immunological techniques training organized by 
Veterinary laboratory Agency, held at London, UK. 
01/10 Wellcome Trust Advanced Course on Genomics and Clinical 
Microbiology organized by Sanger Institute, held at Wellcome trust 
Genome campus Cambridge, UK. 
 
JOURNAL EDITOR AND REVIEWER  
Assistant editor for De Gruyter Open Publishing in Medicine, Pharmacy and Public Health 
(http://degruyteropen.com/people/rfirdessa/), reviewer to European Journal of Cell Biology 
and BMC Veterinary Journal.  
 
TECHNICAL SKILLS  
 
Nanomedicine and nanotechnology: Strong knowledge and research experience in 
nanoparticle/drug formulations and their physicochemical characterizations: determinations of 
size, zeta potential and binding affinity of nanoparticles or nanopolyplexes by dynamic light 
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scattering (DLS), electrophoretic light scattering (ELS), transmission electron micrscopy 
(TEM), electrophoretic mobility shift assay (EMSA), isothermal titration calorimetry (ITC) 
and microscale thermophoresis (MST); polymer nanoparticle-based delivery of small 
molecules, immune modulators and nucleic acids, and testing for efficacy (IC50 
determination), biocompatibility with reporter gene assays (Luciferase transgenic strains) and 
MTT assay.  
Laboratory animal handling: General anaesthesia by isoflurane inhalation via anaesthetic 
machine; over all handling and sampling; taking general clinical parameters including 
footpads swelling and weight;  administration of drugs with/without nanoparticle formulations 
intravenous (tail vein), subcutaneous (foot pad and neck fold) and intraperitoneal; experience 
with mouse surgery, taking organs and stem cells for cell generation; in vivo imaging systems 
(IVIS) of mice infected with reporter gene strains of microbes for determination of drug 
efficacy and longitudinal infection progression studies.   
Molecular biology and immunology techniques: cell and tissue culture, bone marrow 
derived macrophages and dendritic cells generations, cell isolation from mice organs (lymph 
nodes, spleen), TEM, confocal microscopy and fluorescent microscopy with image processing 
tools like Imagej, immunocytochemistry, flow cytometry, western blotting, biological sample 
collection, microbiological culture, biochemical tests, gamma interferon assay, ELISA, 
complement fixation test, competitive ELISA, RT-PCR, DNA extraction, transformation or 
transfection, restriction fragment length polymorphism (RFLP), variable number tandem 
repeats, spoligotyping, multi-locus sequencing, DNA microarray, bioinformatics tools for 
proteomics and genomics and, single nucleotide polymorphisms analysis. 
 
 
 
 
Würzburg, 23.03.2015                                                            Rebuma Firdessa Fite  
 
 
